Top

Jeffrey Joel Molldrem, M.D.

Department of Hematopoietic Biology & Malignancy, Division of Cancer Medicine

Present Title & Affiliation

Primary Appointment

Adjunct Professor, Department of Bioengineering, Division of Cancer Medicine, Rice University, Houston, TX

Professor and Chair, Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor (tenured) (Joint appointment), Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Professor, Department of Bioengineering, Rice University, Houston, Texas

Professor and Chair, Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX

Faculty (tenure track), UT Graduate School for Biomedical Sciences, Clinical and Translational Sciences Program, Houston, TX

Virginia H. Cockrell Distinguished Professorship in Immunology, Department of Stem Cell Transplantation - Research, UT MD Anderson Cancer Center, Houston, TX

Professor (tenured), Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX

Faculty (tenure track), The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Program in Immunology, Houston, TX

Research Interests

The long-term goal of my lab is to develop immunotherapies for leukemia and other hematological diseases through an understanding of T-cell immunity against hematopoietic progenitors. Our central hypothesis is that T-cells target and eliminate these progenitors by recognizing determinants of self-antigens when tolerance has been reversed by aberrant self-antigen expression. As models, we have studied myeloid leukemia and MDS and have found that CD8 lymphocytes recognized the HLA-A2-restricted PR1 peptide, derived from both P3 and NE, due to aberrant subcellular localization and over-expression.

Education & Training

Degree-Granting Education

1990	University of Minnesota, Minneapolis-St. Paul, Minnesota, US, MD
1986	Moorhead State University, Moorhead, Minnesota, US, Chemistry, BA

Postgraduate Training

1993-1996	Clinical Associate and Post-doctoral Fellow, Hematology and Oncology, National Heart, Lung and Blood Institute and National Cancer Institute, Bethesda, Maryland
1993-1997	BMT Fellow, BMT Unit, National Heart, Lung & Blood Institute, National Institutes of Health (NIH), Bethesda, Maryland
1993-1997	Bone Marrow Transplant Fellowship, BMT Unit, Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
1993-1997	Bone Marrow Transplant Fellowship, BMT Unit, Johns Hopkins University, Baltimore, Maryland
1990-1991	Clinical Internship, Internal Medicine, University of California, Los Angeles, California
1990-1993	Clinical Residency, Internal Medicine, University of California, Los Angeles, California

Licenses & Certifications

2001	Texas Controlled Substances Registration Certificate
1999	Texas State Board of Medical Examiners
1996	American Board of Internal Medicine, Diplomate in Hematology
1996	Drug Enforcement Administration
1993	American Board of Internal Medicine, Diplomate in Internal Medicine
1993	Medical Board of California

Experience & Service

Faculty Academic Appointments

Associate Professor (tenured), Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, 2001 - 2005

Assistant Professor (tenure track), Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, 1997 - 2001

Attending Physician, Department of Hematology Branch, NHLBI, NIH, Bethesda, MD, 1996 - 1997

Administrative Appointments/Responsibilities

Co-Leader - Cancer Bioengineering Collaborative, The University of Texas MD Anderson Cancer Center/Rice University, Houston, Texas, 2024 - Present

Institute Director and Head, ECLIPSE (Evolution of Cancer, Leukemia and Immunity Post Stem cEll Transplant), Department of Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present

Scientific Director, Oncology Research for Biologics and Immunotherapy Translation (ORBIT), Department of Therapeutics Discovery Division, UT MD Anderson Cancer Center, Houston, TX, 2015 - Present

Co-Director, Cancer Immunotherapy Fellowship, Department of Cancer Medicine, UT MD Anderson Cancer Center, Houston, TX, 2014 - Present

Program Co-leader, Cancer Center Support Grant (CCSG), Basic Science Programs, Immunology, UT MD Anderson Cancer Center, Houston, TX, 2011 - Present

Program Co-Leader, Cancer Center Support Grant (CCSG), Clinical/Translational Thematic Programs, Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, 2011 - 2018

Co-Director, Center for Cancer Immunology Research (CCIR), Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, 2003 - Present

Chief, Section of Transplantation Immunology, Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, 1999 - Present

Associate Medical Director, Bone Marrow Transplant Lab, Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, 1998 - 2012

Other Professional Positions

Member-Scientific Advisory Board, Alloy Therapeutics, Houston, TX, 2020 - 2023

Scientific Advisory Board, The Mark Foundation, New York, NY, 2017 - 2018

Scientific Advisory Board, The Goodwin Foundation, Kiawah, SC, 2017 - 2018

Immuno-Oncology Scientific Advisory Panel, Genocea Biosciences, Inc., New York, NY, 1/2016-1/2017, Genocea Biosciences, Inc, New York City, NY, 2016 - 2017

Consultantships, Kymab Limited, Cambridge, England, UK, 2015 - 2018

Consultantships, Cell Signaling Technologies, Danvers, Massachusetts, 2014 - 2015

Scientific Advisory Board, Texas Cancer Vaccine, Dallas, 2012

Scientific Advisory Board, Baylor Institute for Immunology Research (BIIR), Houston, TX, 2012

Scientific Advisory Board, Gabrielle's Angel Foundation for Cancer Research, New York, NY, 2010 - 2017

Founder and Director, Scientific Advisory Board, The Vaccine Company, Houston, TX, 2004 - 2009

International Scientific Advisory Committee, Jose Carreras International Leukaemia Foundation, Barcelona, 2003 - 2014

Medical Advisory Board, Aplastic Anemia and Myelodysplasia Foundation, Inc. (AA&MDSIF), Annapolis, MD, 2002 - 2007

Scientific Advisory Panel, Pharmacia, BMT and the future of Atgam, Dallas, TX, 2001

Scientific Advisory Panel, National Cancer Institute of Milan, Milan, 1998

Lieutenant Commander, Grade 0-4, 1993 - 1997

Intramural Institutional Committee Activities

Member, Allison Institute Advisory Council (AIAC), The University of Texas MD Anderson Cancer Center, 2025 - Present

Extramural Institutional Committee Activities

Member, Focus Fund Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, Cell Therapy Working Group Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present

Committee Member, Institutional Conflict of Interest Committee (ICOIC), The University of Texas MD Anderson Cancer Center, 2018 - Present

Member, Technology Task Force, The University of Texas MD Anderson Cancer Center, 2017 - Present

Committee Member, Decisive Discoveries Focus Group, The University of Texas MD Anderson Cancer Center, 2017 - 2019

Committee Member, Enhancing Entrepreneurship, The University of Texas MD Anderson Cancer Center, 2017 - 2018

Member, Division of Cancer Medicine, Department of Hematopoietic Biology and Malignancy Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2016 - 2019

Member, Moon Shot Adoptive Cell Therapy Platform Working Group, The University of Texas MD Anderson Cancer Center, 2016 - Present

Co-chair, Department of Infectious Diseases Search Committee, Physician Scientist, The University of Texas MD Anderson Cancer Center, 2015 - 2016

Member, Institutional Research Executive Committee (IREC), The University of Texas MD Anderson Cancer Center, 2015 - Present

Member, Science that Enables Strategic Planning Committee for Space Metrics, The University of Texas MD Anderson Cancer Center, 2014 - 2016

ad hoc member, Institutional Manufacturing Oversight Advisory Committee (IMOAC), The University of Texas MD Anderson Cancer Center, 2014 - Present

Member, Core Facility Optimization Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2016

Member, Clinical Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present

Member, Effort Reporting Compliance Workgroup, The University of Texas MD Anderson Cancer Center, 2012 - 2016

Member, Immunotherapy Working Group, The University of Texas MD Anderson Cancer Center, 2012 - Present

Member, Immunology Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2013

Member, Monoclonal Antibody Facility Oversight Committee, The University of Texas MD Anderson Cancer Center, 2011

Member, Immune Monitoring Core Lab Board, The University of Texas MD Anderson Cancer Center, 2011

Member, Department of Infectious Diseases Search Committee, Tenure-Track, Assistant Professor, Basic Scientist, The University of Texas MD Anderson Cancer Center, 2010

Member, Laboratory Space Utilization Subcommittee, The University of Texas MD Anderson Cancer Center, 2010 - 2014

Member, Breast Clinical and Translational Immunology Program (BCTIP), The University of Texas MD Anderson Cancer Center, 2010 - 2015

Member, Executive Research Compliance Committee (ERCC), The University of Texas MD Anderson Cancer Center, 2010 - Present

Reviewer, Cancer Prevention and Research Institute of Texas (CPRIT) Letter of Intent Applications, The University of Texas MD Anderson Cancer Center, 2009

Member, Introduction to Research Series for Incoming Fellows, The University of Texas MD Anderson Cancer Center, 2008 - Present

Member, Department of Melanoma Medical Oncology Career Advisory Committee, The University of Texas MD Anderson Cancer Center, 2008

Member, Technology Review Committee for Institutional Grants, The University of Texas MD Anderson Cancer Center, 2008 - Present

Member, Department of Pediatric Research Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2008 - Present

Member, Institute for Personalized Cancer Therapy Working Group (IPCT), The University of Texas MD Anderson Cancer Center, 2008 - Present

Member, Department of Lymphoma/Myeloma Advisory Committee, K99/R00 Application, The University of Texas MD Anderson Cancer Center, 2008

Member, Endowed Positions Awards Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2010

Co-chair, Division of Cancer Medicine, Physician-Scientist Task Force, The University of Texas MD Anderson Cancer Center, 2007 - Present

Member, Department of Immunology Tenure Review Committee, The University of Texas MD Anderson Cancer Center, 2007 - Present

Member, Department of Infectious Diseases Search Committee, Section Chief, The University of Texas MD Anderson Cancer Center, 2006

Member, First Annual Division of Cancer Medicine Faculty Recognition and Award Program, The University of Texas MD Anderson Cancer Center, 2006

Advisor, BCM/MDACC Collaborative Multidisciplinary Research Program, The University of Texas MD Anderson Cancer Center, 2006 - 2008

Member, Department of Lymphoma/Myeloma Search Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2007

Member, EVP/CAO Search Advisory Group, The University of Texas MD Anderson Cancer Center, 2006 - 2007

Member, Clinical Researchers Mentoring Program, The University of Texas MD Anderson Cancer Center, 2005 - Present

Member, Department of Stem Cell Transplantation and Cellular Therapy Departmental Planning Committee, The University of Texas MD Anderson Cancer Center, 2004 - Present

Member, Basic Science Achievement Committee, The University of Texas MD Anderson Cancer Center, 2003

Member, Peptide Synthesis Oversight Committee, The University of Texas MD Anderson Cancer Center, 2003

Member, GMP-Cell Therapy Laboratory Oversight Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2007

Vice Chairman, Research Laboratory Space Subcommittee of the Research Council, The University of Texas MD Anderson Cancer Center, 2003 - 2005

Member, Study Section Review Committee for Basic Research Projects under the Institutional Research Grants Program, The University of Texas MD Anderson Cancer Center, 2003 - 2006

Member, Lymphoma SPORE Mentoring Program, The University of Texas MD Anderson Cancer Center, 2003 - 2006

Member, Board of Visitors, The University of Texas MD Anderson Cancer Center, 2002 - Present

Member, Melanoma SPORE Internal Advisory Committee, The University of Texas MD Anderson Cancer Center, 2002 - Present

Member, Department of Immunology Search Committee, The University of Texas MD Anderson Cancer Center, 2002 - Present

Member, Laboratory Space Utilization Subcommittee, The University of Texas MD Anderson Cancer Center, 2001 - 2006

Preceptor, Division of Cancer Medicine, Hematology/Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, 2001 - Present

Member, Research Funding Oversight Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2006

Representative, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2000 - 2003

Member, Institutional Biosafety Committee, The University of Texas MD Anderson Cancer Center, 1999 - 2001

Member, Department of Immunology Chair Search Committee, The University of Texas MD Anderson Cancer Center, 1999

Member, Department of Bioimmunotherapy Chair Search Committee, The University of Texas MD Anderson Cancer Center, 1999

Member, Institutional Research Grants Program, Study Section Review Committee for Clinical, Translational and Population-based Research Project Funding, The University of Texas MD Anderson Cancer Center, 1999 - 2002

Member, Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 1998 - 1999

Editorial Activities

Editorial Board, Leukemia, 2008 - Present

Editorial Board, Cytotherapy, 2001 - Present

Honors & Awards

2024	David M. Livingston Collaboration Award, Break Through Cancer
2017	Division of Cancer Medicine 2017 Excellence in Entrepreneurship Award, Division of Cancer Medicine
2015	President's Recognition for Faculty Excellence, The University of Texas MD Anderson Cancer Center
2015	Robert M. Chamberlain Distinguished Mentor Award Nominee, The University of Texas MD Anderson Cancer Center
2014	Fellow, American Association for the Advancement of Science
2013	Robert M. Chamberlain Distinguished Mentor Award Nominee, The University of Texas MD Anderson Cancer Center
2009	American Society of Clinical Investigators
2007	Division of Cancer Medicine Mentor Award, Fellowship Program, The University of Texas MD Anderson Cancer Center
2003	Julie and Ben Rogers Award for Excellence, The University of Texas MD Anderson Cancer Center
2001	Faculty Scholar Award, The University of Texas MD Anderson Cancer Center
1993	Solomon Scholars Resident Research Award, University of California Los Angeles
1990	Chugai-Upjohn Sponsored Award, American Society of Hematology
1990	Thomas J. Livermore Award for Outstanding Research in Hematology, University of Minnesota
1989	Minnesota Medical Foundation Research Award, University of Minnesota

Professional Memberships

Society for Immunotherapy of Cancer (SITC)

2015 - Present

American Society of Clinical Oncology

2015 - Present

Clinical Immunotherapy Guidelines (CIG) Task Force, International Society for Biological Therapy of Cancer (iSBTc)

2010 - 2010

American Society of Gene & Cell Therapy

2009 - 2013

Harris County Medical Society

2007 - Present

Texas Medical Association

2007 - Present

The American Association of Immunologists

2006 - Present

American Society for Blood and Marrow Transplantation

2005

International Society for Experimental Hematology

2005 - Present

Jose Carreras International Leukemia Foundation

2003

American Association for Cancer Research

2002 - Present

Aplastic Anemia & MDS International Foundation

2002 - 2007

International Society for Cellular Therapy (formerly ISHAGE)

1999 - 2008

American Association for the Advancement of Science

1997 - Present

American Society of Hematology

1997 - Present

American Society for Blood and Marrow Transplantation

1997 - Present

American College of Physicians

1997

Selected Presentations & Talks

Local Presentations

2025. Therapeutic Antibody Development: From Academic Research to Clinical Application. Invited. IGNITE. Houston, Texas, US.
2025. Nothing Succeeds Like Excess. Invited. Calabresi Scholar Master Class. Houston, Texas, US.
2024. Mapping the T Cell Receptor-Ligand Landscape of GVL: Development of Targeted Immunotherapeutics for AML. Invited. Center for Cell and Gene Therapy (CCGT) Seminar Series. Houston, Texas, US.
2024. High Throughput Target Identification and Development of Novel Engineered Antibodies for AML. Invited. Inaugural Cullen M. Taniguchi Immuno-Radiotherapy Symposium. Houston, Texas, US.
2024. Mapping the Landscape of GVL: Development of Targeted Immunotherapeutics for AML. Conference. Mapping the Landscape of GVL: Development of Targeted Immunotherapeutics for AML. Houston, TX, US.
2023. “Dissecting Graft-Versus”Leukemia immunity to Uncover and Develop Novel Immunotherapeutics”. Conference. “Dissecting Graft-Versus”Leukemia immunity to Uncover and Develop Novel Immunotherapeutics”. Houston, TX, US.
2022. “T cell receptor-mimic antibodies to target intracellular proteins in cancer”. Conference. “T cell receptor-mimic antibodies to target intracellular proteins in cancer”. Houston, TX, US.
2021. "Antibodies for Cancer Immunotherapies". Conference. "Antibodies for Cancer Immunotherapies". Houston, TX, US.
2020. Development of first-in-class T cell receptor-like antibody to treat acute myelogenous leukemia”. Conference. Development of first-in-class T cell receptor-like antibody to treat acute myelogenous leukemia”. Houston, TX, US.
2018. Development of a first-in-class TCR-like monoclonal antibody for AML. Conference. Development of a first-in-class TCR-like monoclonal antibody for AML. Houston, TX, US.
2017. The impact of the tumor microenvironment on antigen presentation. Conference. The impact of the tumor microenvironment on antigen presentation. Houston, TX, US.
2016. Antibiodies: Structure, function, use in biology. Conference. Antibiodies: Structure, function, use in biology. Houston, TX, US.
2015. Targeting neutrophil Elastase (NE) in cancer. Conference. Targeting neutrophil Elastase (NE) in cancer. Houston, TX, US.
2015. Immunotherapy of AML. Conference. Immunotherapy of AML. Houston, TX, US.
2015. Evolution of GvL and GvH adaptive immunity after stem cell transplantation. Conference. Evolution of GvL and GvH adaptive immunity after stem cell transplantation. Houston, TX, US.
2014. TCR-like antibody therapeutic platform for cancer. Conference. TCR-like antibody therapeutic platform for cancer. Houston, TX, US.
2014. A TCR-llke antibody targeting hematopoietic PR1 peptide has broad anti-tumor activity. Conference. A TCR-llke antibody targeting hematopoietic PR1 peptide has broad anti-tumor activity. Houston, TX, US.
2014. Serine proteases neutrophil elastase and proteinase 3 alter the antigen repertoire of the MDA-MB-231 breast cancer cell line (Poster). Conference. Serine proteases neutrophil elastase and proteinase 3 alter the antigen repertoire of the MDA-MB-231 breast cancer cell line (Poster). Houston, TX, US.
2014. PR1-specific cytotoxic T lymphocytes expanded from cord blood are functional in vitro (Poster). Conference. PR1-specific cytotoxic T lymphocytes expanded from cord blood are functional in vitro (Poster). Houston, TX, US.
2014. Characterization of neutrophil elastase receptor in breast cancer: Implication for immunotherapy (Poster). Conference. Characterization of neutrophil elastase receptor in breast cancer: Implication for immunotherapy (Poster). Houston, TX, US.
2014. Neutrophil elastase uptake by breast cancer increases the anti-tumor adaptive immune response by upregulation of HLA Class I molecules (Poster). Conference. Neutrophil elastase uptake by breast cancer increases the anti-tumor adaptive immune response by upregulation of HLA Class I molecules (Poster). Houston, TX, US.
2014. Bi-specific T-cell engaging antibody activates T-cells to target the tumor associated antigen PR1 (Poster). Conference. Bi-specific T-cell engaging antibody activates T-cells to target the tumor associated antigen PR1 (Poster). Houston, TX, US.
2013. Academia & Biotechnology: observations from an academic investigator. Conference. Academia & Biotechnology: observations from an academic investigator. Houston, TX, US.
2013. Targeting hematopoietic antigens for cancer immunotherapy. Conference. Targeting hematopoietic antigens for cancer immunotherapy. Houston, TX, US.
2012. Targeting hematopoietic proteases: a new paradigm for immunotherapy of solid and liquid tumors. Conference. Targeting hematopoietic proteases: a new paradigm for immunotherapy of solid and liquid tumors. Houston, TX, US.
2011. Immunology targeting leukemic stem cells. Conference. Immunology targeting leukemic stem cells. Houston, TX, US.
2010. Immunotherapy of leukemia. Conference. Immunotherapy of leukemia. Houston, TX, US.
2010. Targeted elimination of leukemia stem cells with a monoclonal antibody to the endogenous leukemia antigen PR1. Conference. Targeted elimination of leukemia stem cells with a monoclonal antibody to the endogenous leukemia antigen PR1. Houston, TX, US.
2009. Immunotherapy. Conference. Immunotherapy. Houston, TX, US.
2009. PR1 as an epitope for immunotherapy: hematopoietic target antigens in non-hematopoietic tumors. Conference. PR1 as an epitope for immunotherapy: hematopoietic target antigens in non-hematopoietic tumors. Houston, TX, US.
2008. Immunotherapy in MDS. Conference. Immunotherapy in MDS. Houston, TX, US.
2007. Proteinase 3-derived peptide epitopes to elicit cytotoxic T lymphocytes targeting MDS cells. Conference. Proteinase 3-derived peptide epitopes to elicit cytotoxic T lymphocytes targeting MDS cells. Houston, TX, US.
2007. T-cell immunity to human leukemia. Conference. T-cell immunity to human leukemia. Houston, TX, US.
2006. New treatment strategies in MDS. Conference. New treatment strategies in MDS. Houston, TX, US.
2006. Immunotherapy for myeloid leukemia: Bench to bedside and back. Conference. Immunotherapy for myeloid leukemia: Bench to bedside and back. Houston, TX, US.
2006. Peptide vaccination with leukemia-associated antigens. Conference. Peptide vaccination with leukemia-associated antigens. Houston, TX, US.
2006. Proteinase 3-derived peptide epitopes to elicit cytotoxic T lymphocytes targeting MDS cells. Conference. Proteinase 3-derived peptide epitopes to elicit cytotoxic T lymphocytes targeting MDS cells. Houston, TX, US.
2005. Optimizing T-cell immunotherapy against cancer. Conference. Optimizing T-cell immunotherapy against cancer. Houston, TX, US.
2005. Vaccine therapy for leukemia. Conference. Vaccine therapy for leukemia. Houston, TX, US.
2005. Antigen-specific lymphocytes for GVL. Conference. Antigen-specific lymphocytes for GVL. Houston, TX, US.
2004. Autoimmunity in myelodysplastic syndrome: friend or foe?. Conference. Autoimmunity in myelodysplastic syndrome: friend or foe?. Houston, TX, US.
2004. Is there significant immune therapy in CML?. Conference. Is there significant immune therapy in CML?. Houston, TX, US.
2003. A peptide vaccine induces molecular remission in patients with leukemia. Conference. A peptide vaccine induces molecular remission in patients with leukemia. Houston, TX, US.
2002. Antigen-specific immunotherapy for CML. Conference. Antigen-specific immunotherapy for CML. Houston, TX, US.
2002. Applying allogeneic immunotherapy to the treatment of malignancies. Conference. Applying allogeneic immunotherapy to the treatment of malignancies. Houston, TX, US.
2002. Transplantation and tumor immunology: evolving opportunities. Conference. Transplantation and tumor immunology: evolving opportunities. Houston, TX, US.
2002. Applying allogeneic immunotherapy to the treatment of malignancies. Conference. Applying allogeneic immunotherapy to the treatment of malignancies. Houston, TX, US.
2001. Non-self autoimmunity: a new concept to harvest potent allogeneic anti-tumor immunity. Conference. Non-self autoimmunity: a new concept to harvest potent allogeneic anti-tumor immunity. Houston, TX, US.
1999. Immune tolerance to leukemia. Conference. Immune tolerance to leukemia. Houston, TX, US.
1998. Tissue restricted antigen based vaccine therapy. Conference. Tissue restricted antigen based vaccine therapy. Houston, TX, US.
1997. Targeted immunotherapy strategies for myeloid leukemias. Conference. Targeted immunotherapy strategies for myeloid leukemias. Houston, TX, US.

Regional Presentations

2019. A Novel T Cell Receptor-Like Antibody for AML. Conference. A Novel T Cell Receptor-Like Antibody for AML. Houston, US.
2017. Immunotherapy targeting the tumor-associated antigen cyclin E on lymphoid neoplasms. Conference. Immunotherapy targeting the tumor-associated antigen cyclin E on lymphoid neoplasms. Houston, US.
2017. A T cell receptor-like antibody to the PR1 myeloid leukemia antigen effectively targets cancer stem cells. Conference. A T cell receptor-like antibody to the PR1 myeloid leukemia antigen effectively targets cancer stem cells. Houston, US.
2016. A T cell receptor-like monoclonal antibody (8F4) against PR1/HLA-A2 selectively eliminates acute myeloid leukemia stem cells. Conference. A T cell receptor-like monoclonal antibody (8F4) against PR1/HLA-A2 selectively eliminates acute myeloid leukemia stem cells. Houston, US.
2013. Hematopoietic antigens as targets for cancer immunotherapy. Conference. Hematopoietic antigens as targets for cancer immunotherapy. Dallas, TX, US.

National Presentations

2024. Dissecting Graft-Versus-Leukemia Immunity to Uncover and Develop Novel Immunotherapeutics. Invited. THOR Research Lecture Series. Cleveland, Ohio, US.
2022. Novel T cell Receptor-like Antibodies to Target Cancer Peptide Antigens. Conference. Livestrong Cancer Institutes. Austin, TX, US.
2022. Novel T cell receptor-like antibodies to target cancer peptide antigens. Conference. Livestrong Cancer Institutes at The University of Texas at Austin’s Dell Medical School. Austin, TX, US.
2021. Manipulating Antigen Presentation by Serine Proteases. Conference. Society for Immunotherapy of Cancer (SITC). Virtual Meeting, US.
2021. Potential for T cell receptor-like antibodies for antigen-specific immunotherapy in multiple formats, including ADCC-enhanced, bi/tri-specifics, and as CARs to redirect polyclonal T cells against a T cell target with specificity for the malignant found clones. Conference. SACHS IOIF (IMMUNO=ONCOLOGY INNOVATION FORUM). Virtual Meeting, US.
2017. The role of NET-associate proteins in alloimmunity. Conference. Chronic GVHD Meeting. Chicago, IL, US.
2016. Development of a novel TCR-like bi-specific T cell engager targeting PR1/HLA-A2 leukemia antigen (Poster, Abstract #1497). Conference. American Association for Cancer Research Annual Meeting. New Orleans, LA, US.
2016. Engineering a TCR-like anti-PR1/HLA-A2 antibody scFv in a novel chimeric antigen receptor to redirect T cells to eliminate myeloid leukemia (Poster, Abstract #278). Conference. American Society of Blood and Marrow Transplantation Annual Meeting. Honolulu, HI, US.
2016. T cell receptor-like antibody 8F4 targets leukemia and non-hematopoietic cancer. Conference. American Association for Cancer Research Special Conference, The Function of Tumor Microenvironment in Cancer Progression. San Diego, CA, US.
2015. Neutrophil elastase induces post-transcriptional increase of surface MHC class I expression on lung cancer cells (Poster, Abstract #4049). Conference. American Association for Cancer Research Annual Meeting. Philadelphia, PA, US.
2015. Long-term subclonal evolution of CLL from immune selective pressure after allogeneic stem cell transplant and donor lymphocyte infusion (Late-Breaking Poster Session, Abstract #LB-222). Conference. American Association for Cancer Research Annual Meeting. Philadelphia, PA, US.
2015. Characterization of neutrophil elastase uptake in breast cancer: Implications for immunotherapy (Poster, Abstract #2351). Conference. American Association for Cancer Research Annual Meeting. Philadelphia, PA, US.
2014. Inhibition of T cell proliferation by granulocyte membrane-associated proteinase 3 is reversed by blocking the interaction of calreticulin with LRP on T cells (Poster, Abstract #4110). Conference. American Society of Hematology Annual Meeting. San Francisco, CA, US.
2014. PR1 is cross-presented by multiple myeloma cells in patients and renders multiple myeloma susceptible to PR1-CTL and anti-PR1/HLA-A2 antibody (Poster, Abstract #2133). Conference. American Society of Hematology Annual Meeting. San Francisco, CA, US.
2014. PR1-specific cytotoxic T lymphocytes expanded from cord blood are functional in vitro (VAC11P.1002). Conference. American Association of Immunologists Annual Meeting. Pittsburgh, PA, US.
2014. Bi-specific T-cell engaging antibody activates T-cells to target the tumor associated antigen PR1 (Poster, Abstract #646). Conference. American Association of Cancer Research Annual Meeting. San Diego, CA, US.
2013. PR1-CTL directly sort-purified from umbilical cord blood lymphocytes reduce human AML in vivo (Poster, Abstract #P4360). Conference. American Association of Immunologists Annual Meeting. Honolulu, HI, US.
2012. Multiple myeloma cross-presents neutrophil elastase and proteinase 3 and becomes susceptible to PR1-targeting immunotherapy (Online Publication, Abstract 4973). Conference. 54th Society of Hematology Annual Meeting. Atlanta, GA, US.
2012. Membrane-associated proteinase 3 on granulocytes and myeloid leukemia mediates reversible inhibition of T cell proliferation associated with altered ZAP70 and ERK signaling (Poster, Abstract #1031). Conference. 54th Society of Hematology Annual Meeting. Atlanta, GA, US.
2012. A high frequency of naive PR1-specific CD8+ T cells in umbilical cord blood and fetal thymus suggest incomplete central tolerance to the hematopoietic self-antigen PR1 (Poster, Abstract #46.24). Conference. 99th American Association of Immunologists Annual Meeting. Boston, MA, US.
2012. A T cell receptor-like monoclonal antibody that targets leukemia stem cells. Conference. 2012 American Association for Cancer Research Annual Meeting. Chicago, IL, US.
2011. Treatment with 8F4, an anti-PR1/HLA-A2 T cell receptor-like antibody, reduces established acute myeloid leukemia and eliminates leukemia stem cells in mice (Poster, Abstract #766). Conference. 53rd American Society of Hematology Annual Meeting. San Diego, CA, US.
2011. Membrane-associated proteinase 3 on granulocytes and myeloid leukemia mediates reversible inhibition of T cell proliferation (Poster, Abstract #1916). Conference. 53rd American Society of Hematology Annual Meeting. San Diego, CA, US.
2011. T cells and TCR-like antibodies to treat leukemia. Conference. 14th American Society of Gene & Cell Therapy Annual Meeting. Seattle, WA, US.
2011. Antigen-specific immune therapy for MDS and related myeloid malignancies. Conference. American Society for Blood and Marrow Transplantation Annual Meeting. Honolulu, HI, US.
2010. Surface expression of PR1 peptide on thymic denddritic cells does not eliminate PR1-specific CD8+ cells in umbilical cord blood (Poster, Abstract #959). Conference. 52nd American Society of Hematology Annual Meeting. Orlando, FL, US.
2010. Proteinase 3 mediates enzyme-independent reversible inhibition of CD4 and CD8 T cell proliferation by blocking G1-S transition (Poster, Abstract #2089). Conference. 52nd American Society of Hematology Annual Meeting. Orlando, FL, US.
2010. Grant writing: basic/translational applications. Conference. 52nd American Society of Hematology Annual Meeting. Orlando, FL, US.
2010. Cellular uptake of soluble neutrophil elastase increases cyclin E isoform expression and significantly augments susceptibility of breast cancer cells to cytolysis by CCNE-specific cytotoxic T lymphocytes (Poster, Abstract #2090). Conference. 52nd American Society of Hematology Annual Meeting. Orlando, FL, US.
2010. Peripheral tolerance to PR1 is maintained after uptake of soluble proteinase-3 and neutrophil elastase (Oral Presentation, Abstract #4301). Conference. 52nd American Society of Hematology Annual Meeting. Orlando, FL, US.
2010. Soluble inflammatory mediators proteinase-3 and neutrophil elastase are targeted by PR1-specific immunotherapy after cellular uptake and cross presentation of PR1 peptide by breast cancer cells (Poster, Abstract #2089). Conference. 52nd American Society of Hematology Annual Meeting. Orlando, FL, US.
2009. Anti-PR1/HLA-A2 antibody (8F4, a TCR-mimic) mediates specific lysis of AML stem cells but not normal hematopoietic stem cells (Abstract #15). Conference. 51st American Society of Hematology Annual Meeting. New Orleans, LA, US.
2009. T-cell immunity to two HLA-A2-restricted self-determinants of cyclin E may contribute to remission after stem cell transplantation (Abstract #686). Conference. 51st American Society of Hematology Annual Meeting. New Orleans, LA, US.
2009. LFA-1 regulates CD8+ T cell activation through both TCR-mediated and LFA-1-mediated Erk 1/2 signal pathways (Poster, Abstract #35.16). Conference. The 96th American Association of Immunologists Annual Meeting. Seattle, WA, US.
2008. Genomics as a tool for antigen discovery in allogeneic stem cell transplantation: Identification of the minor antigen T4A through donor/patient polymorphism disparities (Poster, Abstract #3907). Conference. 50th American Society of Hematology Annual Meeting. San Francisco, CA, US.
2008. Proteinase 3 mediates direct inhibition of CD4 and CD8 T lymphocyte proliferation by inducing enzyme-independent G0/G1 cell cycle arrest (Publication, Abstract #4916). Conference. 50th American Society of Hematology Annual Meeting. San Francisco, CA, US.
2008. Leukemia-associated primary granule proteins elastase-2 and proteinase-3 are aberrantly expressed in solid tumors: A potential therapeutic target for PR1-directed immunotherapy (Publication, Abstract #5440). Conference. 50th American Society of Hematology Annual Meeting. San Francisco, CA, US.
2008. Direct visualization of PR1/HLA-A2 on the membrane of HLA-A2+CD13+CD33+ myeloid leukemia blasts by a novel monoclonal antibody (Poster, Abstract #2545). Conference. 50th American Society of Hematology Annual Meeting. San Francisco, CA, US.
2008. Peptide vaccine for leukemia. Conference. 99th American Society for Cancer Research Annual Meeting. San Diego, CA, US.
2008. Mistrafficking of primary granule proteins in leukemia simultaneously prmotes PGP cross-priming and increases susceptibility to CTL killing (Oral Presentation, Abstract #1034). Conference. 98th American Assocation of Cancer Research Annual Meeting. San Diego, CA, US.
2007. T-cell autoimmunity may contribute to neutropenia in a patient with cyclic neutropenia and double de-novo mutations in Gfi-1 (Poster, Abstract #3298). Conference. 49th American Society of Hematology Annual Meeting. Atlanta, GA, US.
2007. Aberrant subcellular localization of azurophil granule proteins in myeloid leukemia favors peptide antigen presentation on MHC-I and susceptibility to killing by cytotoxic T lymphocytes (Poster, Abstract #4900). Conference. 49th American Society of Hematology Annual Meeting. Atlanta, GA, US.
2007. PR1 vaccine elicited immunological response after hematopoietic stem cell transplantation is associated with better clinical response and event-free survival (Oral Session, Abstract #577). Conference. 49th American Society of Hematology Annual Meeting. Atlanta, GA, US.
2007. PR1 peptide vaccine-induced immune response is associated with better event-free survival in patients with myeloid leukemia (Oral Presentation, Abstract #283). Conference. 49th American Society of Hematology Annual Meeting. Atlanta, GA, US.
2007. Aberrantly expressed neutrophil elastase in the nucleus and cytoplasm of acute lymphocytic leukemia cells cleaves cyclin E into low-molecular-weight forms yielding novel HLA-A2 restricted determinants (Poster, Abstract #50.28). Conference. 94th American Association of Immunologists Annual Meeting. Miami Beach, FL, US.
2007. CD8 T cells with high avidity TCR-ab specific for serine protease self-determinants for use in adoptive immunotherapy of human leukemia (Poster, Abstract #48.35). Conference. 94th American Association of Immunologists Annual Meeting. Miami Beach, FL, US.
2007. Ex vivo expansion of PR1-CTL elicited by autologous dendritic cells pulsed with PR1 peptide for adoptive immunotherapy of leukemia (Poster, Abstract #B157). Conference. 94th American Association of Immunologists Annual Meeting. Miami Beach, FL, US.
2007. Overexpressed circulating serine proteases are a predominant source of self-antigen for potent T lymphocyte immunity to human leukemia (Poster, Abstract #48.5). Conference. 94th American Association of Immunologists Annual Meeting. Miami Beach, FL, US.
2007. Peptide vaccination against serine proteases reverse T-cell tolerance and eliminates leukemia stem cells. Conference. 2007 Keystone Symposia on Molecular and Cellular Biology. Keystone, CO, US.
2007. GCSF decreases CD4+CD25+CD127 low regulatory T cell proliferation index in stem cell donors (Poster, Abstract #355). Conference. American Society for Blood and Marrow Transplantation Annual Meeting. San Diego, CA, US.
2007. CTL with specificity for cyclin E self-antigen peptides contribute to remission after stem cell transplantation without associated graft-versus-host disease (Poster, Abstract #80). Conference. American Society of for Blood and Marrow Transplantation Annual Meeting. Keystone, CO, US.
2006. A mouse model of PR1-CTL adoptive cell therapy demonstrates rapid reduction of leukemia burden in both bone marrow and extramedullary organs (Poster, Abstract #3682). Conference. 48th American Society of Hematology Annual Meeting. Orland, FL, US.
2006. Abberantly expressed neutrophil elastase cleaves cyclin E in the nucleus and cytoplasm of acute lymphocytic leukemia yielding novel leukemia-associated antigens (Poster). Conference. 48th American Society of Hematology Annual Meeting. Orlando, FL, US.
2006. Elevated serum neutrophil elastase but not proteinase 3 is present in patients with myeloid leukemia. Conference. 48th American Society of Hematology Annual Meeting. Orlando, FL, US.
2006. Generation of cytotoxic T-cell responses. Conference. 10th Biennial Symposium on Hematopoietic Cell Transplantation. Stanford, CA, US.
2006. High avidity PD-1 cyclin E-specific CTL contribute to leukemia remission and may be induced by eptiope spread (Poster). Conference. American Association of Immunologists Annual Meeting. Boston, MA, US.
2006. How close are we to using vaccines for myeloid leukemia?. Conference. Acute Leukemia Form 2006: Advances and Controversies in the Biology and Therapy of Acute Myelogenous Leukemia. San Francisco, CA, US.
2006. PR1 vaccine after hematopoietic stem cell transplantation (Oral Presentation). Conference. American Society of Blood and Marrow Transplantation Annual Meeting. Honolulu, HI, US.
2006. Peptide vaccination with leukemia-associated antigens (Plenary Session). Conference. 2006 American Society for Blood and Marrow Transplantation Annual Meeting. Honolulu, HI, US.
2005. Pre-existing anti-GM-CSF autoantibodies in patients with AML, CML and MDS are associated with compromised immune response to PR1 peptide vaccination (Poster, Abstract #3257). Conference. 47th American Society of Hematology Annual Meeting. New Orleans, LA, US.
2005. PR1 leukemia-assoicated antigen is cross-presented by B cells from soluble serum proteases (Poster, Abstract #2397). Conference. 47th American Society of Hematology Annual Meeting. New Orleans, LA, US.
2005. High avidity cyclin E-derived peptide-specific CTL contribute to induction of remission after stem cell transplantation without associated graft-versus-host disease (Poster, Abtract #1424). Conference. 47th American Society of Hematology Annual Meeting. New Orleans, LA, US.
2005. Antigen-specific immunotherapy for myeloid leukemia. Conference. Myeloid Disease Committee. Los Angeles, CA, US.
2005. High avidity cyclin E1-derived peptide-specific CTL kill lymphoid leukemia cells and cross-recognized a homologous cyclin E1-derived peptide (Poster). Conference. American Society for Blood and Marrow Transplantation Annual Meeting. Keystone, CO, US.
2004. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia (Oral Session, Abstract #259). Conference. 46th American Society of Hematology Annual Meeting. San Diego, CA, US.
2004. High avidity cyclin E1-derived peptide-specific kill lymphoid leukemia cells and cross-recognized a homologous cyclin E2-derived peptide (Poster, Abstract #4498). Conference. 46th American Society of Hematology Annual Meeting. San Diego, CA, US.
2004. Press Conference, Peptide vaccine can produce complete remission in myeloid leukemia patients. Conference. 46th American Society of Hematology Annual Meeting. San Diego, CA, US.
2004. Antigen cross-presentation allows the PR1 leukemia-associated antigen to be processed from both proteinase 3 and neutrophil elastase to prime T cells (Poster, Abstract #3245). Conference. 46th American Society of Hematology Annual Meeting. San Diego, CA, US.
2004. IgG, IgA and IgM autoantibodies to GM-CSF are present in AML, CML and MDS patients and IgG titer is associated with disease progression (Poster, Abstract #1071). Conference. 46th American Society of Hematology Annual Meeting. San Diego, CA, US.
2004. Is there significant immune therapy in CML?. Conference. Leukemia 2004 - towards the cure. Houston, TX, US.
2003. Cyclin E2 peptide-specific CTL clone shows cross recognition of homologous cyclin E1 peptide and kills lymphoid and myeloid leukemia cells (Poster, Abstract #2595). Conference. 45th American Society of Hematology Annual Meeting. San Diego, CA, US.
2003. The PR1 leukemia-associated antigen is endogeneously processed and presented from both proteinase 3 and neutrophil elastase and is recognized by T lymphocytes (Poster, Abstract #2571). Conference. 45th American Society of Hematology Annual Meeting. San Diego, CA, US.
2003. Immunotherapy of hematologic malignancy (Education Session). Conference. 45th American Society of Hematology Annual Meeting. San Diego, CA, US.
2003. PR1 peptide vaccination of myeloid leukemia patients induces PR1-specific CTL with high CCR7 expression (Poster, Abstract #2257). Conference. 45th American Society of Hematology Annual Meeting. San Diego, CA, US.
2003. Immunomodulation in MDS: Pathophysiology and treatment. Conference. Evolution in Current and Novel Therapies in MDS: An Up-to-the-Minute Report. San Diego, CA, US.
2003. Molecular remission of relapsed leukemia and active immunity induced by peptide vaccination. Conference. 94th American Association for Cancer Research Annual Meeting. Washington, DC, US.
2003. Vaccine studies in myeloid malignancies: data from peptide vaccination with PR1. Conference. CALGB Spring Committee Meeting. Chicago, IL, US.
2003. The leukemia-associated antigen PR1 is derived from both proteinase 3 and neutrophil elastase proteins (Poster, Abstract #92). Conference. American Society of Blood and Marrow Transplantation Annual Meeting. Keystone, CO, US.
2003. Dendritic cells cultured with interferon plus GM-CSF can be used to elicit PR1-specific CTL for adoptive immunotherapy (Poster, Abstract #101). Conference. American Society of Blood and Marrow Transplantation Annual Meeting. Keystone, CO, US.
2003. Two HLA-A2-restricted peptides from cyclin E1 and cyclin E2 elicit CTL that kill myeloid leukemia cell line (Poster, Abstract #2). Conference. American Society of Blood and Marrow Transplantation Annual Meeting. Keystone, CO, US.
2003. Immunosuppression treatment of MDS with ATG (equine) (Satellite Symposium). Conference. 2003 American Society of Blood and Marrow Transplantation Annual Meeting. Keystone, CO, US.
2002. High affinity PR1-specific T cells participate in the maintenance of cytogenetic remission in interferon-sensitive chronic myelogenous leukemia patients off all therapy, (Poster, Abstract #618). Conference. 44th American Society of Hematology Annual Meeting. Philadelphia, PA, US.
2002. Definitive evidence for an immunodominance heirarchy in the human CD8+ T cell response to cytomegalovirus (Poster, Abstract #5209). Conference. 44th American Society of Hematology Annual Meeting. Philadelphia, PA, US.
2002. A single nucleotide polymorphism in proteinase 3 that codes for HLA-A2-binding peptides protects against development of acute myelogenous leukemia (Poster, Abstract #2194). Conference. 44th American Society of Hematology Annual Meeting. Philadelphia, PA, US.
2002. Peptide vaccination with PR1 elicits active T cell immunity that induces cytogenetic remission in acute myelogenous leukemia (Plenary Session, Abstract #8). Conference. 44th American Society of Hematology Annual Meeting. Philadelphia, PA, US.
2002. Autologous bone marrow-derived antigens drive clonal expansions of T cells that secrete interferon-gamma and TNF-Alpha in patients with myelodysplastic syndrome and cytopenia (Poster, Abstract #1440). Conference. 44th American Society of Hematology Annual Meeting. Philadelphia, PA, US.
2002. Press Conference, Peptide vaccine helps build immunity to leukemia cells. Conference. 44th American Society of Hematology Annual Meeting. Philadelphia, PA, US.
2002. Antigen-specific T lymphocytes to treat hematological malignancies (Education Session). Conference. 93rd American Association for Cancer Research Annual Meeting. San Francisco, CA, US.
2002. Novel targeted therapies. Conference. American Society of Hematology Highlights Review Conference. Tysons Corner, VA, US.
2001. Effective specific immunity induced after PR1 peptide vaccination correlates with cytogenetic remission (Poster, Abstract #1708). Conference. 43rd American Society of Hematology Annual Meeting. Orlando, FL, US.
2001. Immunity to a novel myeloperoxidase peptide, proteinase 3 and the HA-1 minor antigen is present in AML patients that respond to nonablative stem cell transplant (Poster, Abstract #3551). Conference. 43rd American Society of Hematology Annual Meeting. Orlando, FL, US.
2001. Peptide/MHC monomers can be inserted into artificial lipid bilayers as artifical antigen presentation constructs (Poster, Abstract #2126). Conference. 43rd American Society of Hematology Annual Meeting. Orlando, FL, US.
2001. Induction of a high affinity allogeneic PR1-specific CTL response is associated with cytogenetic remission after PR1 peptide vaccine (Poster, Abstract #2735). Conference. 43rd American Society of Hematology Annual Meeting. Orlando, FL, US.
2001. Advances in targeted therapies. Conference. 43rd American Society of Hematology Annual Meeting. Orlando, FL, US.
2001. The role of immunotherapy in allogeneic stem cell transplantation. Conference. American Association of Blood Banks Annual Meeting. San Antonio, TX, US.
2001. Nonmyeloablative stem cell transplant as a platform for antigen-specific immunotherapy (Plenary Session). Conference. 2001 American Society for Blood and Marrow Transplantation Annual Meeting. Keystone, CO, US.
2000. Molecular analysis of the T cell repertoire reveals dominant clonal T cells that persist in ATG-refractory MDS patients (Poster, Abstract #3602). Conference. 42nd American Society of Hematology Annual Meeting. San Francisco, CA, US.
2000. Expression of the leukemia-associated antigen proteinase 3 and neutrophil elastase is transcriptionally upregulated by interferon-a2b and GM-CSF in CD34+ CML cells (Poster, Abstract #733). Conference. 42nd American Society of Hematology Annual Meeting. San Francisco, CA, US.
2000. Cytotoxic T lymphocytes (CTL) specific for myeloperoxidase-derived HLA-A2-restricted peptides specifically lyse AML and CML cells (Poster, Abstract #3291). Conference. 42nd American Society of Hematology Annual Meeting. San Francisco, CA, US.
2000. Self-antigens as targets for vaccines and allotherapies. Conference. American Society for Blood and Marrow Transplantation Annual Meeting. Anaheim, CA, US.
1999. Survival of T-LGL leukemia cells is associated with expression and constitutive activation of the anti-apoptosis receptor RANK and RANK ligand on T-LGL cells (Poster, Abstract #4496). Conference. 41st American Society of Hematology Annual Meeting. New Orleans, LA, US.
1999. Cytotoxic T lymphocytes (CTL) specific for the PR1 leukemia antigen are increased in the majority of CML patients with complete cytogentic responses to interferon and in allogeneic bone marrow transplant recipients (Poster, Abstract #5159). Conference. 41st American Society of Hematology Annual Meeting. New Orleans, LA, US.
1999. Cytotoxic T lymphocytes (CTL) recognize a HLA-A2.1-restricted peptide derived from myeloperoxidase, a leukemia-associated protein (Poster). Conference. 41st American Society of Hematology Annual Meeting. New Orleans, LA, US.
1999. Treatment with low-dose cyclosporine induces sustained recovery from cytopenia in patients with T-LGL leukemia (Poster, Abstract #5154). Conference. 41st American Society of Hematology Annual Meeting. New Orleans, LA, US.
1999. CD26 as a marker for clinically aggressive T-LGL leukemia (Poster). Conference. 41st American Society of Hematology Annual Meeting. New Orleans, LA, US.
1999. High dose antigen induces apoptosis of high avidity cytoxic T lymphocytes specific for a myeloid self-peptide (Poster, Abstract #2036). Conference. Keystone Symposia on Molecular and Cellular Biology, US.

International Presentations

2020. Targeted immunotherapy of AML with novel T cell receptor-like monoclonal antibody. Conference. The Hematology Experts Summit Forum. Shanghai, CN.
2019. T Cell Receptor-Like Monoclonal Antibodies: Novel Therapeutics for Hematological Malignancies. Conference. Hematopoietic Malignancy and Immunotherapy Symposium. Cangzhou, CN.
2019. T Cell Receptor -Like Monoclonal Antibodies: Novel Therapeutics For Hematological Malignancies. Conference. Hematopoietic Biology and Immunotherapy Symposium. China, CN.
2018. Harnessing alloimmunity to treat cancer. Conference. Global Academic Programs-MDACC. Stockholm, SE.
2016. Targeting leukemia-associated antigens with T cell receptor-like antibodies. Conference. European Hematology Association - EHA21. Copenhagen, DK.
2016. Humanized anti-PR1/HLA-A2 antibody H8F4 induces apoptosis of human acute myeloid leukemia (Poster). Conference. 2016 Keystone Symposia: Molecular and Cellular Biology. Vancouver, CA.
2016. Subclonal evolution of chronic lymphocytic leukemia (CLL) after allogeneic T-cell immunotherapies (Poster, Abstract #1025). Conference. 2016 Keystone Symposia: The Cancer Genome. Banff, CA.
2015. T cell receptor-like antibody 8F4 targets leukemia and non-hematopoietic cancer. Conference. International Conference for Antibody Therapeutics. Taipei, TW.
2011. Future directions: New roads to bypass GVHD. Conference. Focus on Advances in the Diagnosis & Management of Graft-Versus-Host Disease. Buenos Aires, AR.
2010. Antigen-specific targeted immunotherapy of myeloid malignancies. Conference. 6th Symposium on Haploidentical Stem Cell Transplantation. Jerusalem, IL.
2009. PR peptide vaccine. Conference. 14th Congress of the European Hematology Association. Berlin, DE.
2007. T-cell immunity to human leukemia (Education Session). Conference. 43rd American Society of Clinical Oncology Annual Meeting. Chicago, US.
2006. Peptide vaccination for human leukemia. Conference. Looking Toward the Future. Bermuda, GB.
2006. Vaccinating transplant recipients. Conference. 5th Benjamin Franklin Stem Cell Workshop. Berlin, DE.
2006. New treatment strategies in MDS. Conference. Centro Congressi, International Workshop on Immune-Mediated Marrow Failure. Naples, IT.
2005. Unmasking self antigens as vaccine targets (Education Session). Conference. 3rd European Society of Hematology International Conference. Genoa, IT.
2005. Immune Surveillance in MDS. Conference. Bone Marrow Failure Disease Scientific Symposium. Washington, US.
2005. Proteinase-3-derived peptides to induce CTLs activity in leukemia. Conference. Palazzo della Cultura e dei Congressi. Bologna, IT.
2005. Immunosuppressive therapy with ATG in low-risk patients with myelodysplastic syndrome. Conference. 8th International Symposium on Myelodysplastic Syndromes, MDS 2005. Nagasaki, JP.
2005. Immunotherapy with leukemia-associated antigens for induction of GVL responses after allogeneic BMT. Conference. Cellular Therapy 2005. Regensburg, DE.
2004. PR1 peptide vaccines. Conference. Focus on Biological Therapies in Hematologic Malignancies. Siena, IT.
2004. Is there significant immune therapy in CML? (Abstract #GS013). Conference. 3rd International Meeting of the Global Organization Against Leukemia. Houston, US.
2004. Prognosis and treatment of myelodysplastic syndromes (Education Session). Conference. 2004 American Society of Clinical Oncology Annual Meeting. New Orleans, US.
2004. Primary granule proteins as targets of immunotherapy for myeloid forms of leukemia (Abstract). Conference. International Society for Cellular Therapy Annual Meeting. Dublin, IE.
2004. Primary granules proteins as targets of immunotherapy for myeloid forms of leukemia (Plenary Session). Conference. 2004 International Society for Cellular Therapy Annual Meeting. Dublin, IE.
2003. Immunity versus tolerance after vaccination for leukemia. Conference. European School of Haematology International Conference on Chronic Myeloid Leukaemia. Rapallo, IT.
2003. Cytotoxic T-cell vaccines. Conference. European Hematology Association International Conference on Chronic Myeloid Leukemia. Rapallo, IT.
2003. Interferon-induced antigen-specific immunity against CML. Conference. Tokyo Hematology Seminar. Tokyo, JP.
2003. Strategies for developing guidelines for diagnosis and treatment of the myelodysplastic syndromes. Conference. 65th Annual Meeting of the Japanese Society of Hematology and the 45th Annual Meeting of the Japanese Society of Clinical Hematology. Osaka, JP.
2003. Peptide vaccination of myeloid leukemia. Conference. Regenerative & Cell Therapy: Clinical Advances. Paris, FR.
2003. Predicting response of patients with MDS to antithymocyte globulin by T cell clonal dominance (Abstract). Conference. 65th annual Meeting of the Japanese Society of Hematology and the 45th Annual Meeting of the Japanese Society of Clinical Hematology, JP.
2002. Prognostic and therapeutic role of proteinase 3 specific immunity. Conference. 4th International Dresden Symposium on Immunotherapy of Cancer. Dresden, DE.
2002. Allogeneic responses against self-peptides for the treatment of leukemia (Plenary Session). Conference. 8th International Society for Hematotherapy and Graft EngineeringAnnual Meeting. Barcelona, ES.
2002. The treatment of MDS with antithymocyte globulin (Satellite Symposium). Conference. 28th European Group for Blood and Marrow Transplantation Annual Meeting. Montreux, CH.
2002. Graft versus tumor effect (Education Session). Conference. 28th European Group for Blood and Marrow Transplantation Annual Meeting. Montreux, CH.
2002. Anti PR1 CTL relevance in NST and other potential targets. Conference. 3rd International Workshop on Non-Myeloablative Stem Cell Transplantation. Captiva Island, US.
2001. Evidence that specific T lymphocytes may participate in the elimination of CML. Conference. 30th International Society for Experimental Hematology Annual Meeting. Tokyo, JP.
2001. Proteinase 3-specific CTL for the treatment of leukemia. Conference. 7th International Society for Hematotherapy and Graft Engineering Annual Meeting. Quebec City, CA.
2001. Allogeneic immunotherapy and unrelated stem cell grafting (Education Session). Conference. 37th American Society of Clinical Oncology Annual Meeting. San Francisco, US.
2000. Clonal T cell suppression of hematopoiesis in myelodysplastic syndrome. Conference. 42nd Japanese Society of Clinical Hematology Annual Meeting. Kurashiki, JP.
2000. Characterization and isolation of antigen-specific T cells for immunotherapy. Conference. 6th International Society of Hematotherapy and Grant Engineering Annual Meeting. San Diego, US.
2000. Proteinase 3 specific T cell responses for autologous and allogeneic immunotherapy. Conference. 4th Herman Boerhaave Symposium. Leiden, NL.
1996. Cytotoxic T lymphocytes specific for a MHC class I-restricted peptide derived from the leukemia-associated protein proteinase 3 also shows specificity toward fresh leukemic cells (Poster, Abstract #1059). Conference. 33rd American Society of Clinical Oncology Annual Meeting, US.

Formal Peers

2024. Dissecting Graft-Versus-Leukemia Immunity to Uncover and Develop Novel Immunotherapeutics. Invited. Cleveland, OH, US.
2022. MD/PhD Seminar Series: Topics in Molecular Medicine. Invited. Houston, TX, US.
2020. "Development of a first-in-class T cell receptor-like antibody to treat acute myelogenous leukemia". Invited. Houston, TX, US.
2017. A T cell receptor-like antibody to the PR1 myeloid leukemia antigen effectively targets cancer stem cells. Invited. Houston, US.
2016. T cell receptor-like antibody 8F4 targets leukemia and non-hematopietic cancer. Invited. Houston, TX, US.
2015. Cell therapy: From the bench to the bedside and return, "Immunobiology of allogeneic transplantation". Invited. Los Alcazares, ES.
2015. Myeloid serine proteases as targets and regulators of anti-tumor immunity. Invited. New York, NY, US.
2015. Myeloid serine proteases as targets and regulators of anti-tumor immunity. Invited. Minneapolis, MN, US.
2014. Targeting leukemia with T cell receptor-like antibody molecules. Invited. Chapel Hill, NC, US.
2014. Advances in Immunotherapy in Hematologic Malignancies / Tumor Antigens for Cancer Immunotherapy. Invited. Buenos Aires, AR.
2013. Targeting myeloid antigens for cancer immunotherapy. Invited. New York, NY, US.
2012. A central role for hematopoietic proteases as ubiquitous tumor antigens and potent regulators of anti-tumor immunity. Invited. Ann Arbor, MI, US.
2012. Immunity to hematopoietic serine proteases to treat leukemia. Invited. New York, NY, US.
2011. Immune mechanism by which interferons affect CML. Invited. New York, NY, US.
2011. Future directions: New roads to bypass GVHD. Invited. Buenos Aires, AR.
2010. Antigen-specific targeted immunotherapy of myeloid malignancies. Invited. Jerusalem, IL.
2008. Cellular Therapy. Invited. Hilton Head Island, SC, US.
2008. Immunotherapeutic targets for AML. Invited. Vancouver, CA.
2008. Immunotherapy for leukemia: At the crossroads of inflammation and autoimmunity. Invited. Stanford, CA, US.
2007. Immune pathophysiology/pathogenesis of MDS. Invited. Cleveland, OH, US.
2007. Peptide vaccination against serine proteases reverse T-cell tolerance and eliminates leukemia stem cells. Invited. Chapel Hill, NC, US.
2006. Modulation of immunity in MDS. Invited. New York, NY, US.
2005. Leukemia-specific cellular immunity. Invited. Seattle, WA, US.
2005. Vaccine-induced T-cell immunity to human myeloid leukemia. Invited. Long Island, NY, US.
2005. Immunity to human leukemia. Invited. Philadelphia, PA, US.
2005. Leukemia vaccines. Invited. Washington, US.
2004. Antigen-specific immunotherapy for myeloid leukemia. Invited. Buffalo, NY, US.
2004. T cell immunity to myeloid leukemias. Invited. Boston, MA, US.
2004. T cell immunity to myeloid leukemias. Invited. New Haven, CT, US.
2004. T cell immunity to myeloid leukemias. Visiting. New Haven, CT, US.
2004. T cell targeting of hematopoietic progenitors. Invited. Stanford, CA, US.
2003. Identifying major resources needing supplementation in regards to myeloproliferative, myelodysplastic, and marrow failure syndromes (MPS/MDS/MFS. Invited. Bethesda, MD, US.
2002. Redirecting allogeneic T-cell immunity to self-antigens for immunotherapy. Invited. Baltimore, MD, US.
2002. Immune therapy for AML. Invited. Bethesda, MD, US.
2002. T-cell targeting of hematopoietic progenitors. Invited. Minneapolis, MN, US.
2001. Directing T-cell alloimmunity against self antigens for immunotherapy. Invited. Bethesda, MD, US.
2001. The mechanisms of immune mediated cytopenias in MDS. Invited. Las Colinas, TX, US.
2001. Immunotherapy for leukemia. Invited. Fargo, ND, US.
2001. Thymoglobulin in MDS and aplastic anemia. Invited. Scottsdale, AZ, US.
2001. Using antigen-specific T cells to eliminate leukemia. Invited. Dallas, TX, US.
2000. Vaccination of human myeloid leukemia. Invited. Kanazawa, JP.
2000. Clonal evolution of aplastic anemia and myelodysplastic syndrome. Invited. Hartford, CT, US.
2000. Myelodysplastic syndromes. Invited. Los Angeles, CA, US.
1998. Treatment of myelodysplastic syndromes with ATG. Invited. Los Angeles, CA, US.
1998. Antithymocyte globulin treatment for myelodysplastic syndrome. Invited. Dallas, TX, US.
1997. Large granular lymphocytic leukemia. Invited. Bethesda, MD, US.
1997. Human T-LGL leukemia: a model for T cell-mediated hematopoietic attack. Invited. Bethesda, MD, US.
1996. Targeted immunotherapy for myeloid leukemias. Invited. Bethesda, MD, US.
1996. Treatment of myelodysplastic syndromes with ATG. Invited. Baltimore, MD, US.
1996. Myelodysplastic syndromes: recent advances in therapeutics. Invited. Pamplona, ES.
1996. Overview of the myelodysplastic syndromes: pathophysiology and treatment. Invited. Washington, US.
1996. The potential of cellular-mediated autoimmunity to treat leukemia. Invited. Baltimore, MD, US.

Less

Grant & Contract Support

Date:	2025 - 2030
Title:	Species-specific basis for severe congenital neutropenia
Funding Source:	Cleveland Clinic/NIH
Role:	PI

Date:	2025 - 2028
Title:	Biophysical Modeling to Quantify T Cell Recognition of Hematologic Neoantigens and Viral Peptides in the Setting of Hematopoietic Stem Cell Transplant
Funding Source:	TAMU/CPRIT
Role:	PI

Date:	2025 - 2028
Title:	DEVELOPMENT OF MULTIMERIC NANOCAR T CELLS AGAINST AML
Funding Source:	CPRIT
Role:	Collaborator

Date:	2024 - 2027
Title:	Development of Nanocar T Cells Against BC Intracellular Antigens
Funding Source:	Department of Defense
Role:	PI
ID:	BC240606

Date:	2023 - 2026
Title:	Targeting Clonal Hematopoiesis (CH) to Prevent Acute Myeloid Leukemia (AML)
Funding Source:	Break Through Cancer - BTC
Role:	Co-PI

Date:	2023 - 2026
Title:	Identifying, Understanding, and Eradicating Measurable Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
Funding Source:	Break Through Cancer - BTC
Role:	Co-PI

Date:	2022 - 2023
Title:	Personalizing CAR T-cell therapy; Collaboration ID: ECLIPSE:BCell-0131
Funding Source:	M. D. Anderson Moon Shots
Role:	Principal Investigator-MDACC

Date:	2021 - 2026
Title:	Impact of clonal hematopoiesis mutations on toxicity and outcomes following oncologic therapy
Funding Source:	NIH/NCI
Role:	Mentor
ID:	PA-20-203

Date:	2020 - 2021
Title:	Anti-PR1 Immune Therapy for Myeloid Leukemia
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	Mentor
ID:	ASCO Young Investigator Award

Date:	2020 - 2025
Title:	Elucidating human leukemia and T cell interactions within the tumor microenvironment
Funding Source:	NIH/NCI
Role:	Mentor
ID:	K08CA248458

Date:	2020 - 2023
Title:	Off the Shelf, Cord-Derived iNK T Cells Engineered to Prevent GVHD and Relapse After Hematopoietic Stem
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP200023

Date:	2020 - 2022
Title:	T-Cell Targeting for GVHD
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01-HI056067

Date:	2018 - 2023
Title:	Novel Cord Blood Derived Cell Therapies
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	2-PO1-CA148600

Date:	2018 - 2020
Title:	B-Cell Lymphoma Moon Shot Program - Flagship 4
Funding Source:	UT MDACC
Role:	Subproject Leader
ID:	Moon Shot Program

Date:	2015 - 2016
Title:	Investigating Regulatory Role of Invariant Natural Killer T Cell In Allogeneic Stem Cell Transplantation
Funding Source:	University of Texas MD Anderson Cancer Center
Role:	Mentor
ID:	Amy Stretzler Manasevit Early Career Award

Date:	2015 - Present
Title:	h8F4 Technology
Funding Source:	Astellas Pharma, Inc
Role:	PI

Date:	2014 - 2016
Title:	Pre-clinical Development of h8F4
Funding Source:	Gillson Longenbaugh Foundation
Role:	PI
ID:	Vanguard Charitable Endowment Program (#396818)

Date:	2014 - 2019
Title:	AML/MDS Moon Shot Program, Flagship 2 Subproject
Funding Source:	M. D. Anderson Moon Shots
Role:	Co-I

Date:	2014 - 2016
Title:	High Risk Multiple Myeloma, Pilot Project 1: Targeting novel cross-presented antigens in high-risk multiple myeloma
Funding Source:	M. D. Anderson Moon Shots
Role:	Co-Leader

Date:	2014 - 2016
Title:	Identification of Imunoregulatory Role of Invariant Natural Killer T Cells From Cord Blood and Ex Vivo Modulation of Regulatory Function Via Th2-Skewing Alpha-GalCer Analogues
Funding Source:	American Society for Blood and Marrow Transplantation
Role:	Mentor
ID:	New Investigator Award

Date:	2014 - 2016
Title:	Keck/CPRIT: Computational Cancer Biology Training Program of the Gulf Coast Consortia
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Mentor
ID:	RP140113

Date:	2013 - 2023
Title:	Cancer Center Support Grant, Immunology Program
Funding Source:	NIH/NCI
Role:	Co-Program Leader
ID:	P30-CA016672

Date:	2013 - 2018
Title:	Cancer Center Support Grant, Stem Cell Transplantation and Cellular Therapy Program
Funding Source:	NIH/NCI
Role:	Program Co-Leader
ID:	5-P30-CA016672-40

Date:	2013 - 2018
Title:	Pre-Clinical Development of an Anti-PR1/HLA-A2 Antibody as a Novel Therapeutic Agent for Myeloid Leukemia
Funding Source:	Goodwin Funds
Role:	PI
ID:	37546

Date:	2011 - 2015
Title:	An Anti-PR1-HLA-A2 Antibody as Novel Therapy for Myeloid Leukemia
Funding Source:	Leukemia and Lymphoma Society
Role:	PI
ID:	6030-12

Date:	2011 - 2017
Title:	Improving Cord Blood Transplantation (PP-4)
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	5-P01-CA148600-05

Date:	2011
Title:	Development of Monoclonal Antibody
Funding Source:	M. D. Anderson Cancer Center
Role:	Investigator
ID:	104504

Date:	2011
Title:	T Cell Receptor Like Antibody
Funding Source:	Gillson Longenbaugh Foundation
Role:	PI
ID:	109957

Date:	2011 - 2016
Title:	Therapy of CML, Immune Assessment Core (PC-E)
Funding Source:	NIH/NCI
Role:	Co-I
ID:	2-P01-CA049639-24 (PC-E)

Date:	2011
Title:	General Research Fund
Funding Source:	Gift
Role:	Investigator
ID:	104552

Date:	2010
Title:	Immune System Leukemia Research Fund
Funding Source:	Gift
Role:	Investigator
ID:	104553

Date:	2010 - 2016
Title:	The Future of Cancer Research: Training Program for Basic and Translational Scientists
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Consult
ID:	RP140106

Date:	2010
Title:	Large Granular Lymphocytosis Research
Funding Source:	Gift, Research Allocation
Role:	Investigator
ID:	104471

Date:	2009
Title:	Leukemia Associated Proteins
Funding Source:	Gillson Longenbaugh Foundation
Role:	Investigator
ID:	104474

Date:	2008 - 2010
Title:	Cyclin E: Implications for Targeted Therapy in HER2-overexpressing Breast Cancer
Funding Source:	NIH/NCI
Role:	Mentor
ID:	K99-CA133244

Date:	2008 - 2013
Title:	Genome-wide Identification of Minor Histocompatibility Antigens
Funding Source:	NIH/NCI
Role:	Mentor
ID:	K25-CA123344

Date:	2008 - Present
Title:	NO TITLE PROVIDED
Funding Source:	Patent Royalty Funds
Role:	Investigator
ID:	104486

Date:	2007 - 2009
Title:	Anti-leukemia Immunity Following PR1 Vaccine Therapy
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	Mentor
ID:	Young Investigator Award

Date:	2007 - 2009
Title:	Identifying Novel Leukemia Antigens Through Stem Cell Transplant Donor/Patient Polymorphism Disparities
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	Mentor
ID:	Young Investigator Award

Date:	2007 - 2008
Title:	Identification of Novel Leukemia Antigens through Stem Cell Transplant Donor/Patient Polymorphism Disparities
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	Mentor
ID:	ASCO Young Investigator Award

Date:	2007 - 2008
Title:	Anti-leukemia Immunity following PR1 Vaccine Therapy
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	Mentor
ID:	ASCO Young Investigator Award

Date:	2007 - 2012
Title:	Translational Development of Novel Vaccine Therapies
Funding Source:	Leukemia and Lymphoma Society
Role:	Project Leader
ID:	7262-08 (PP-3)

Date:	2007 - 2011
Title:	Cyclin E-derived Peptides as Targets of T Lymphocyte Mediated Immunity Against Leukemia
Funding Source:	Carl C. Anderson Sr. and Marie Jo Anderson Charitable Foundation
Role:	PI
ID:	616250-03

Date:	2007 - 2011
Title:	Cyclin E-derived Peptides as Targets of T Lymphocyte Mediated Immunity Against Leukemia
Funding Source:	Gillson Longenbaugh Foundation
Role:	PI
ID:	9091.001-G 2007 03

Date:	2007 - 2012
Title:	Genome-Wide Interaction of Minor-Histocompatibility Antigens
Funding Source:	NIH/NCI
Role:	Mentor
ID:	1K25CA-123344-01A1

Date:	2006 - 2009
Title:	Targeted Immune Therapy with Cell Cycle Protein-Derived Antigen
Funding Source:	Leukemia and Lymphoma Society
Role:	PI
ID:	6031-07-03

Date:	2006 - 2011
Title:	DC vaccination to enhance adoptive T cell transfer
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	R01-CA111999-05

Date:	2006
Title:	Sponsored Projects
Funding Source:	Gift
Role:	Investigator
ID:	104526

Date:	2006 - Present
Title:	Virginia Cockrell Distinguished Professor in Immunology
Funding Source:	M. D. Anderson Cancer Center
Role:	Investigator
ID:	104561

Date:	2005 - 2011
Title:	New Approaches to the Biology and Treatment of MDS (PP-5)
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	P01-CA108631-05 (PP-5)

Date:	2005 - 2008
Title:	Cellular Immunology of Cancer
Funding Source:	M. D. Anderson Cancer Center
Role:	Investigator
ID:	104480

Date:	2005 - 2008
Title:	MoFlo Cytometry Facility Allocation
Funding Source:	M. D. Anderson Cancer Center
Role:	Core Director
ID:	104479

Date:	2005 - 2009
Title:	DM97-325 Antigen Specific Immunotherapy of Myeloid Leukemia
Funding Source:	Gillson Longenbaugh Foundation
Role:	PI

Date:	2004
Title:	The Phil Pitchford Fund for Leukemia Immunotherapy Research
Funding Source:	Gift
Role:	Investigator
ID:	104489

Date:	2004 - 2010
Title:	Regulation of Dendritic Cell-mediated Homeostatic Proliferation of Human CD4 Cells by TSLP
Funding Source:	NIH/NIAID
Role:	Consult
ID:	R01-AI062888

Date:	2004
Title:	Various Donors for Myelodysplastic Syndrome
Funding Source:	Gift
Role:	Investigator
ID:	104554

Date:	2003 - 2010
Title:	Therapy of CML, Tissue Procurement and Cell Bank
Funding Source:	NIH/NCI
Role:	Core Leader
ID:	P01-CA049639-19 (PC-E)

Date:	2003 - 2010
Title:	Therapy of CML
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	P01-CA049639-19 (PP-3)

Date:	2003 - 2023
Title:	SPORE in Leukemia, Project 2:Anti-PR1 for Myeloid Leukemia
Funding Source:	NIH/NCI
Role:	Co-Program Leader
ID:	2-P50-CA100632-14 (PP2)

Date:	2003
Title:	NO TITLE PROVIDED
Funding Source:	Dr. George P. Smerlis Memorial Fund for BMT Research
Role:	Investigator
ID:	104457

Date:	2002 - 2005
Title:	Faculty Scholar Award
Funding Source:	M. D. Anderson Cancer Center
Role:	Investigator

Date:	2002 - 2003
Title:	Immune Responses in CML Patients Treated with GM-CSF and Interferon
Funding Source:	Immunex Corporation
Role:	PI

Date:	2001 - 2004
Title:	Antigen-Specific Adoptive Immunotherapy for Hematological Malignancies
Funding Source:	G & P Charitable Foundation for Cancer Research
Role:	PI
ID:	CF01-182-03

Date:	2001 - 2001
Title:	Tetrameric Isolation of Antigen-specific CTL for Adoptive Immunotherapy
Funding Source:	R.W. Johnson Pharmaceutical Research Institute
Role:	PI
ID:	LS01-064-1

Date:	2001 - 2006
Title:	Immunotherapy of Low-Risk Myelodysplastic Syndrome
Funding Source:	NIH/NCI
Role:	PI
ID:	R01-CA85843-05

Date:	1999 - 2013
Title:	NO TITLE PROVIDED
Funding Source:	Pharmacia & Upjohn Foundation
Role:	Investigator
ID:	104488

Date:	1974 - 2015
Title:	Training Program in Cancer Immunobiology
Funding Source:	NIH/NCI
Role:	Program Leader
ID:	5-T32-CA009598-25

Selected Publications

Peer-Reviewed Articles

Smallbone, PI, Mendt Vilchez, MC, Sackstein, R, Tanner, MR, Kaur, I, Basar, R, Rafei, H, Daher, M, Overman, B, Al-Atrash, G, Alousi, AM, Bashir, Q, Hosing, C, Im, JS, Kebriaei, P, Banerjee, PP, Patel, KP, Zou, J, Cao, K, Khouri, IF, Mehta, RS, Molldrem, JJ, Nieto, Y, Oran, B, Popat, UR, Qazilbash, MH, Rondon, G, Saini, N, Srour, S, Champlin, RE, Rezvani, K, Shpall, E, Olson, AL. Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftment. Cytotherapy 28(3), 2026. e-Pub 2026. PMID: 41396090.
Sanchez, JR, Liu, C, Pawar, V, Huang, Y, Diaz-Rohena, DY, Singh, J, Koppikar, P, Lai, TH, St John, L, Puduvalli, VK, Molldrem, JJ, Thandapani, P, Jain, N, Lapalombella, R, Sampath, D. NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia. Leukemia and Lymphoma 67(1):97-107, 2026. e-Pub 2026. PMID: 41401031.
Ma, L, Koehn, B, Zaiken, M, Hippen, KL, Smith, K, Allred, J, Williams, R, Yao, K, Fink, J, Saha, A, Koop, B, Payne, N, Widelak, R, Panoskaltsis-Mortari, A, Riddle, MJ, Tolar, J, Eide, C, Xia, L, Witty, AD, Mehta, AK, Denholtz, M, Hefazi, M, Hani, S, Kenderian, S, Miller, J, Molldrem, JJ, Kean, LS, Valamehr, B, Blazar, BR. Inflammasome-resistant IPSC-derived myeloid-derived suppressor cells ameliorate xenogeneic graft-versus-host disease. Blood 146(17):2047-2062, 2025. e-Pub 2025. PMID: 40700578.
Li D, Bassett R, Champlin RE, Molldrem JJ, Mak TW, Ma Q. 2-Methoxyestradiol Treatment Prevents Graft-versus-Host Disease While Preserving Graft-versus-Leukemia Effect in Mice. bioRxiv, 2025. e-Pub 2025. PMID: 40832212.
Yan, J, Shi, C, Yang, G, Tian, Z, Torikai, H, Sukhumalchandra, P, Peng, S, Chang, E, Cui, M, Kerros, C, Philips, A, Qiao, N, Zhang, M, Lofton, T, Allen, J, Gonzalez, MA, Patchametla, S, Sergueeva, A, St John, L, He, H, Zha, D, Molldrem, JJ, Al-Atrash, G. T cell receptor mimic CAR T cells targeting cathepsin G signal peptide. Leukemia 39(8):1948-1959, 2025. e-Pub 2025. PMID: 40437170.
Li D, Shi S, Cao Q, Sood AK, Molldrem JJ, Ma Q, Li C. Copper Sulfide Nanoparticle-Mediated Photothermolysis Induces Immunogenic Cell Death in Ovarian Cancer Cells. bioRxiv, 2025. e-Pub 2025. PMID: 40777257.
Uryu, H, Saeki, K, Haeno, H, Kapadia, C, Furudate, D.M.D., Ph.D., K, Nangalia, J, Spencer Chapman, M, Zhao, L, Hsu, JI, Zhao, C, Chen, S, Tanaka, T, Li, Z, Ogata, S, Hanache, S, Yang, H, DiNardo, C, Daver, N, Pemmaraju, N, Jain, N, Ravandi-Kashani, F, Zhang, J, Song, X, Thompson, EJ, Tang, H, Little, L, Gumbs, C, Orlowski, R, Qazilbash, MH, Bhalla, K, Colla, S, Kantarjian, HM, Kanagal Shamanna, R, Bueso-Ramos, CE, Nakada, D, Al-Atrash, G, Molldrem, JJ, Futreal, A, Shpall, E, Goodell, MA, Garcia-Manero, G, Takahashi, K. Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation. Nature Genetics 57(7):1695-1707, 2025. e-Pub 2025. PMID: 40596442.
Kim, WJ, Crosse, EI, De Neef, E, Etxeberria, I, Sabio, EY, Wang, E, Bewersdorf, J, Lin, KT, Lu, SX, Belleville, A, Fox, N, Castro, C, Zhang, P, Fujino, T, Lewis, J, Rahman, J, Zhang, B, Winick, JH, Lewis, AM, Stanley, RF, DeWolf, S, Urben, BM, Takizawa, M, Krause, T, Molina, H, Chaligné, R, Koppikar, P, Molldrem, JJ, Gigoux, M, Merghoub, T, Daniyan, A, Chandran, SS, Greenbaum, B, Klebanoff, CA, Bradley, RK, Abdel-Wahab, O. Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias. Cell 188(13):3422-3440.e24, 2025. e-Pub 2025. PMID: 40273911.
McCurry D, Ge Z, Lee J, Pasumarthi R, Leng X, Koehnke T, Pasvolsky O, Raparla P, Nguyen V, Maurer K, Li S, Livak KJ, Danson E, Thakkar B, Azizi E, Soiffer RJ, Shukla SA, Majeti R, Ritz J, Wu CJ, Molldrem JJ, Bachireddy P. ASXL1 truncating mutations drive leukemic resistance to T cell attack. bioRxiv, 2025. e-Pub 2025. PMID: 40661385.
Ghoreyshi ZS, Tubo N, Zammataro L, Mao X, Ngai H, Wang D, Chen Y, He Q, Cisneros E, Liang S, Koppikar PJ, Lin X, Molldrem JJ, George JT. Biophysical modeling for accurate T cell specificity prediction of viral and tumor antigens. bioRxiv, 2025. e-Pub 2025. PMID: 40501772.
Shi, C, Tian, Z, Yan, J, Zhang, M, Sukhumalchandra, P, Chang, E, Yang, G, You, J, Cui, M, Shi, Q, Kerros, C, Philips, A, Qiao, N, Torikai, H, Patchametla, S, Sergueeva, A, St John, L, He, H, Wiederschain, D, Lee, BH, Paulus, GL, Zha, D, Molldrem, JJ, Al-Atrash, G. Immunotherapy targeting a leader sequence cathepsin G-derived peptide. Leukemia 39(4):888-898, 2025. e-Pub 2025. PMID: 39939820.
Grefe, M, Trujillo-Ocampo, A, Clinton, J, He, H, Yu, L, Li, D, Ma, Q, Shpall, E, Molldrem, JJ, Im, JS. Cord blood-derived iNK T cells as a platform for allogeneic CAR T cell therapy. Frontiers in immunology 16, 2025. e-Pub 2025. PMID: 40519924.
He, H, Vedia, RA, Lu, S, Li, Q, Cox, K, St John, L, Sergueeva, A, Dwyer, KC, Al-Atrash, G, Shpall, E, Ma, Q, Molldrem, JJ. Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo. Cytotherapy 26(11):1331-1340, 2024. e-Pub 2024. PMID: 39033444.
Hayase, E, Hayase, T, Mukherjee, A, Stinson, SC, Jamal, M, Ortega, MR, Sanchez, CA, Ahmed, S, Karmouch, J, Chang, C, Flores, I, McDaniel, L, Brown, AN, El-Himri, RK, Chapa, V, Tan, L, Tran, B, Xiao, Y, Fan, C, Pham, D, Halsey, T, Jin, Y, Tsai, W, Prasad, R, Glover, I, Enkhbayar, A, Mohammed, A, Schmiester, M, King, KY, Britton, RA, Reddy, P, Wong, M, Ajami, NJ, Wargo, J, Shelburne, S, Okhuysen, PC, Liu, C, Fowler, S, Conner, ME, Katsamakis, Z, Smith, N, Burgos da Silva, M, Ponce, DM, Peled, JU, van den Brink, MR, Peterson, CB, Rondon, G, Molldrem, JJ, Champlin, RE, Shpall, E, Lorenzi, PL, Mehta, RS, Martens, EC, Alousi, AM, Jenq, RR. Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease. Cell Host and Microbe 32(9):1621-1636.e6, 2024. e-Pub 2024. PMID: 39214085.
Jin Y, Miyama T, Brown A, Hayase T, Song X, Singh AK, Huang L, Flores II, McDaniel LK, Glover I, Halsey TM, Prasad R, Chapa V, Ahmed S, Zhang J, Rai K, Peterson CB, Lizee G, Karmouch J, Hayase E, Molldrem JJ, Chang CC, Tsai WB, Jenq RR. Tsyn-seq: a T cell synapse-based antigen identification platform. Cancer Immunol Res 12(5), 2024. e-Pub 2024. PMID: 38363296.
Boda AR, Liu AJ, Castro-Pando S, Whitfield BT, Molldrem JJ, Al-Atrash G, Di Francesco ME, Jones P, Ager CR, Curran MA. Identification of Nonfunctional Alternatively Spliced Isoforms of STING in Human Acute Myeloid Leukemia. Cancer Res Commun 4(3):911-918, 2024. e-Pub 2024. PMID: 38477596.
Boda, A, Liu, A, Castro-Pando, S, Whitfield, BT, Molldrem, JJ, Al-Atrash, G, Di Francesco, ME, Jones, PH, Ager, CR, Curran, M. Identification of Nonfunctional Alternatively Spliced Isoforms of STING in Human Acute Myeloid Leukemia. Cancer Research Communications 4(3):911-918, 2024. e-Pub 2024. PMID: 38477596.
Tian Z, Shi C, Yang G, Allen JK, Shi Q, Al-Shami A, Olson JW, Smith MG, Chang Q, Kaur J, You J, Lofton TE, Gonzalez MA, Zhang Q, Zha D, Tasian SK, Jain N, Konopleva MY, Heffernan T, Molldrem JJ. Correction: Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL. Leukemia 38(1):226, 2024. e-Pub 2024. PMID: 38036631.
Tian Z, Shi C, Yang G, Allen JK, Shi Q, Al-Shami A, Olson JW, Smith MG, Chang Q, Kaur J, You J, Lofton TE, Gonzalez MA, Zhang Q, Zha D, Tasian SK, Jain N, Konopleva MY, Heffernan T, Molldrem JJ. Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL. Leukemia 37(10):2006-2016, 2023. e-Pub 2023. PMID: 37634013.
Lee SE, Wang F, Grefe M, Trujillo-Ocampo A, Ruiz-Vasquez W, Takahashi K, Abbas HA, Borges P, Antunes DA, Al-Atrash G, Daver N, Molldrem JJ, Futreal A, Garcia-Manero G, Im JS. Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes. Clin Cancer Res 29(10):OF1-OF14, 2023. e-Pub 2023. PMID: 36988276.
Hayase E, Hayase T, Mukherjee A, Stinson SC, Jamal MA, Ortega MR, Sanchez CA, Ahmed SS, Karmouch JL, Chang CC, Flores II, McDaniel LK, Brown AN, El-Himri RK, Chapa VA, Tan L, Tran BQ, Pham D, Halsey TM, Jin Y, Tsai WB, Prasad R, Glover IK, Ajami NJ, Wargo JA, Shelburne S, Okhuysen PC, Liu C, Fowler SW, Conner ME, Peterson CB, Rondon G, Molldrem JJ, Champlin RE, Shpall EJ, Lorenzi PL, Mehta RS, Martens EC, Alousi AM, Jenq RR. Bacteroides ovatus alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease. Res Sq, 2023. e-Pub 2023. PMID: 36778495.
Schwabkey ZI, Wiesnoski DH, Chang CC, Tsai WB, Pham D, Ahmed SS, Hayase T, Ortega Turrubiates MR, El-Himri RK, Sanchez CA, Hayase E, Frenk Oquendo AC, Miyama T, Halsey TM, Heckel BE, Brown AN, Jin Y, Raybaud M, Prasad R, Flores I, McDaniel L, Chapa V, Lorenzi PL, Warmoes MO, Tan L, Swennes AG, Fowler S, Conner M, McHugh K, Graf T, Jensen VB, Peterson CB, Do KA, Zhang L, Shi Y, Wang Y, Galloway-Pena JR, Okhuysen PC, Daniel-MacDougall CR, Shono Y, Burgos da Silva M, Peled JU, van den Brink MRM, Ajami N, Wargo JA, Reddy P, Valdivia RH, Davey L, Rondon G, Srour SA, Mehta RS, Alousi AM, Shpall EJ, Champlin RE, Shelburne SA, Molldrem JJ, Jamal MA, Karmouch JL, Jenq RR. Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med 14(671):eabo3445, 2022. e-Pub 2022. PMID: 36383683.
Hayase E, Hayase T, Jamal MA, Miyama T, Chang CC, Ortega MR, Ahmed SS, Karmouch JL, Sanchez CA, Brown AN, El-Himri RK, Flores II, McDaniel LK, Pham D, Halsey T, Frenk AC, Chapa VA, Heckel BE, Jin Y, Tsai WB, Prasad R, Tan L, Veillon L, Ajami NJ, Wargo JA, Galloway-Peña J, Shelburne S, Chemaly RF, Davey L, Glowacki RWP, Liu C, Rondon G, Alousi AM, Molldrem JJ, Champlin RE, Shpall EJ, Valdivia RH, Martens EC, Lorenzi PL, Jenq RR. Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease. Cell 185(20):3705-3719.e14, 2022. e-Pub 2022. PMID: 36179667.
Lu S, Tallis E, Ding X, Li D, Cox K, You MJ, St John L, Alatrash G, Ma Q, Molldrem JJ. Novel myeloperoxidase-derived HLA-A2-restricted peptides as therapeutic targets against myeloid leukemia. Cytotherapy 23(9):793-798, 2021. e-Pub 2021. PMID: 34215503.
Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):JCO2002608, 2021. e-Pub 2021. PMID: 33929874.
Lee SE, Wang F, Trujillo-Ocampo A, Ruiz-Vasquez W, Cho HW, Takahashi K, Molldrem JJ, Futreal A, Garcia-Manero G, Im JS. Fidelity of peripheral blood for monitoring genomics and tumor immune-microenvironment in myelodysplastic syndromes. EJHaem 1(2):552-557, 2020. e-Pub 2020. PMID: 35844984.
He H, Kondo Y, Ishiyama K, Alatrash G, Lu S, Cox K, Qiao N, Clise-Dwyer K, St John L, Sukhumalchandra P, Ma Q, Molldrem JJ. Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia. Leukemia 34(6):1626-1636, 2020. e-Pub 2020. PMID: 31908357.
Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica 104(12):e555-e557, 2019. e-Pub 2019. PMID: 30948491.
Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biol Blood Marrow Transplant 25(7):1347-1354, 2019. e-Pub 2019. PMID: 30826465.
Nahas MR, Stroopinsky D, Rosenblatt J, Cole L, Pyzer AR, Anastasiadou E, Sergeeva A, Ephraim A, Washington A, Orr S, McMasters M, Weinstock M, Jain S, Leaf RK, Ghiasuddin H, Rahimian M, Liegel J, Molldrem JJ, Slack F, Kufe D, Avigan D. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine. Br J Haematol 185(4):679-690, 2019. e-Pub 2019. PMID: 30828801.
Alatrash G, Qiao N, Zhang M, Zope M, Perakis AA, Sukhumalchandra P, Philips AV, Garber HR, Kerros C, St John LS, Khouri MR, Khong H, Clise-Dwyer K, Miller LP, Wolpe S, Overwijk WW, Molldrem JJ, Ma Q, Shpall EJ, Mittendorf EA. Fucosylation enhances the efficacy of adoptively transferred antigen-specific cytotoxic T lymphocytes. Clin Cancer Res 25(8):2610-2620, 2019. e-Pub 2019. PMID: 30647079.
Capello M, Vykoukal JV, Katayama H, Bantis LE, Wang H, Kundnani DL, Aguilar-Bonavides C, Aguilar M, Tripathi SC, Dhillon DS, Momin AA, Peters H, Katz MH, Alvarez H, Bernard V, Ferri-Borgogno S, Brand R, Adler DG, Firpo MA, Mulvihill SJ, Molldrem JJ, Feng Z, Taguchi A, Maitra A, Hanash SM. Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nat Commun 10(1):254, 2019. e-Pub 2019. PMID: 30651550.
Yang TH, St John LS, Garber HR, Kerros C, Ruisaard KE, Clise-Dwyer K, Alatrash G, Ma Q, Molldrem JJ. Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation. J Immunol 201(5):1389-1399, 2018. e-Pub 2018. PMID: 30021768.
Lansford JL, Dharmasiri U, Chai S, Hunsucker SA, Bortone DS, Keating JE, Schlup IM, Glish GL, Collins EJ, Alatrash G, Molldrem JJ, Armistead PM, Vincent BG. Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens. Blood Adv 2(16):2052-2062, 2018. e-Pub 2018. PMID: 30115642.
Trujillo-Ocampo A, Cho HW, Herrmann AC, Ruiz-Vazquez W, Thornton AB, He H, Li D, Qazilbash MA, Ma Q, Porcelli SA, Shpall EJ, Molldrem J, Im JS. Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy 20(8):1089-1101, 2018. e-Pub 2018. PMID: 30076070.
Alatrash G, Perakis AA, Kerros C, Peters HL, Sukhumalchandra P, Zhang M, Jakher H, Zope M, Patenia R, Sergeeva A, Yi S, Young KH, Philips AV, Cernosek AM, Garber HR, Qiao N, Weng J, St John LS, Lu S, Clise-Dwyer K, Mittendorf EA, Ma Q, Molldrem JJ. Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma. Clin Cancer Res 24(14):3386-3396, 2018. e-Pub 2018. PMID: 29661776.
Alatrash G, Molldrem JJ, Qazilbash MH. Targeting PR1 in myeloid leukemia. Oncotarget 9(4):4280-4281, 2018. e-Pub 2018. PMID: 29435102.
Herrmann AC, Im JS, Pareek S, Ruiz-Vasquez W, Lu S, Sergeeva A, Mehrens J, He H, Alatrash G, Sukhumalchandra P, St John L, Clise-Dwyer K, Zha D, Molldrem JJ. A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2. Front Immunol 9:3153, 2018. e-Pub 2018. PMID: 30713535.
Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, Clifton GT, Sukhumalchandra P, Ma Q, Reddy SM, Yu D, Molldrem JJ, Peoples GE, Alatrash G, Mittendorf EA. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Res 77(19):5374-5383, 2017. e-Pub 2017. PMID: 28819024.
Kerros C, Tripathi SC, Zha D, Mehrens JM, Sergeeva A, Philips AV, Qiao N, Peters HL, Katayama H, Sukhumalchandra P, Ruisaard KE, Perakis AA, St John LS, Lu S, Mittendorf EA, Clise-Dwyer K, Herrmann AC, Alatrash G, Toniatti C, Hanash SM, Ma Q, Molldrem JJ. Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells. J Biol Chem 292(24):10295-10305, 2017. e-Pub 2017. PMID: 28468826.
Kolonin MG, Sergeeva A, Staquicini DI, Smith TL, Tarleton CA, Molldrem JJ, Sidman RL, Marchiò S, Pasqualini R, Arap W. Interaction between Tumor Cell Surface Receptor RAGE and Proteinase 3 Mediates Prostate Cancer Metastasis to Bone. Cancer Res 77(12):3144-3150, 2017. e-Pub 2017. PMID: 28428279.
Peters HL, Tripathi SC, Kerros C, Katayama H, Garber HR, St John LS, Federico L, Meraz IM, Roth JA, Sepesi B, Majidi M, Ruisaard K, Clise-Dwyer K, Roszik J, Gibbons DL, Heymach JV, Swisher SG, Bernatchez C, Alatrash G, Hanash S, Molldrem JJ. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunol Res 5(4):319-329, 2017. e-Pub 2017. PMID: 28254787.
Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia 31(3):697-704, 2017. e-Pub 2017. PMID: 27654852.
Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, Perakis AA, Becker L, Yoo SY, Dwyer KC, Coombes K, Talukder AH, John LSS, Senyukov V, Lee DA, Sergeeva A, He H, Ma Q, Armistead PM, Roszik J, Mittendorf EA, Molldrem JJ, Hawke D, Lizee G, Kornblau SM. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia 31(1):234-237, 2017. e-Pub 2017. PMID: 27573556.
Khan M, Carmona S, Sukhumalchandra P, Roszik J, Philips A, Perakis AA, Kerros C, Zhang M, Qiao N, John LSS, Zope M, Goldberg J, Qazilbash M, Jakher H, Clise-Dwyer K, Qiu Y, Mittendorf EA, Molldrem JJ, Kornblau SM, Alatrash G. Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target. Front Immunol 8:1975, 2017. e-Pub 2017. PMID: 29422892.
Ma Q, Garber HR, Lu S, He H, Tallis E, Ding X, Sergeeva A, Wood MS, Dotti G, Salvado B, Ruisaard K, Clise-Dwyer K, John LS, Rezvani K, Alatrash G, Shpall EJ, Molldrem JJ. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy 18(8):985-94, 2016. e-Pub 2016. PMID: 27265873.
St John LS, Wan L, He H, Garber HR, Clise-Dwyer K, Alatrash G, Rezvani K, Shpall EJ, Bollard CM, Ma Q, Molldrem JJ. PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. Cytotherapy 18(8):995-1001, 2016. e-Pub 2016. PMID: 27378343.
Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 128(2):297-312, 2016. e-Pub 2016. PMID: 27247137.
Sergeeva A, He H, Ruisaard K, St John L, Alatrash G, Clise-Dwyer K, Li D, Patenia R, Hong R, Sukhumalchandra P, You MJ, Gagea M, Ma Q, Molldrem JJ. Activity of 8F4, a T cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo. Leukemia 30(7):1475-84, 2016. e-Pub 2016. PMID: 27055866.
Chawla A, Alatrash G, Philips AV, Qiao N, Sukhumalchandra P, Kerros C, Diaconu I, Gall V, Neal S, Peters HL, Clise-Dwyer K, Molldrem JJ, Mittendorf EA. Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells. Cancer Immunol Immunother 65(6):741-51, 2016. e-Pub 2016. PMID: 27129972.
Tripathi SC, Peters HL, Taguchi A, Katayama H, Wang H, Momin A, Jolly MK, Celiktas M, Rodriguez-Canales J, Liu H, Behrens C, Wistuba II, Ben-Jacob E, Levine H, Molldrem JJ, Hanash SM, Ostrin EJ. Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proc Natl Acad Sci U S A 113(11):E1555-64, 2016. e-Pub 2016. PMID: 26929325.
Im JS, Herrmann AC, Bernatchez C, Haymaker C, Molldrem JJ, Hong WK, Perez-Soler R. Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer. PLoS One 11(7):e0160004, 2016. e-Pub 2016. PMID: 27467256.
Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-92, 2015. e-Pub 2015. PMID: 25778529.
Li H, Tong P, Gallegos J, Dimmer E, Cai G, Molldrem JJ, Liang S. PAND: A distribution to identify functional linkage from networks with preferential attachment property. PLoS One 10(7):e0127968, 2015. e-Pub 2015. PMID: 26158709.
Raymond A, Liu B, Liang H, Wei C, Guindani M, Lu Y, Liang S, St John LS, Molldrem J, Nagarajan L. A role for BMP-induced homeobox gene MIXL1 in acute myelogenous leukemia and identification of type I BMP receptor as a potential target for therapy. Oncotarget 5(24):12675-93, 2014. e-Pub 2014. PMID: 25544748.
Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, Stringaris K, Parmar S, Shah N, Shaim H, Yvon E, Molldrem J, Rouce R, Champlin R, McNiece I, Mauri C, Shpall EJ, Rezvani K. Regulatory B-cells are enriched within the IgM memory and transitional subsets in healthy donors but deficient in chronic Graft-Versus-Host disease. Blood 124(13):2034-2045, 2014. e-Pub 2014. PMID: 25051962.
Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2(4):361-70, 2014. e-Pub 2014. PMID: 24764583.
Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, Shah N, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard CM, Shpall EJ. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy 16(1):90-100, 2014. e-Pub 2014. PMID: 24480547.
Dondossola E, Rangel R, Guzman-Rojas L, Barbu EM, Hosoya H, St John LS, Molldrem JJ, Corti A, Sidman RL, Arap W, Pasqualini R. CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A 110(51):20717-22, 2013. e-Pub 2013. PMID: 24297924.
Wu MC, Maity A, Lee S, Simmons EM, Harmon QE, Lin X, Engel SM, Molldrem JJ, Armistead PM. Kernel machine SNP-set testing under multiple candidate kernels. Genet Epidemiol 37(3):267-75, 2013. e-Pub 2013. PMID: 23471868.
Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, Mittendorf EA, Sergeeva A, Ruisaard K, Al-Atrache Z, Ropp PA, Jakher H, Rodriguez-Cruz T, Lizee G, Clise-Dwyer K, Lu S, Molldrem JJ, Glish GL, Armistead PM, Alatrash G. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res 19(1):247-57, 2013. e-Pub 2013. PMID: 23147993.
Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One 8(4):e60031, 2013. e-Pub 2013. PMID: 23560068.
Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ. Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy. J Immunol 189(11):5476-84, 2012. e-Pub 2012. PMID: 23105141.
de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 2012. e-Pub 2012. PMID: 23234514.
Ma Q, Li D, Nurieva R, Patenia R, Bassett R, Cao W, Alekseev AM, He H, Molldrem JJ, Kroll MH, Champlin RE, Sale GE, Afshar-Kharghan V. Reduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation. Biol Blood Marrow Transplant 18(8):1174-81, 2012. e-Pub 2012. PMID: 22664751.
Mittendorf EA, Alatrash G, Qiao N, Wu Y, Sukhumalchandra P, St John LS, Philips AV, Xiao H, Zhang M, Ruisaard K, Clise-Dwyer K, Lu S, Molldrem JJ. Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anti-cancer adaptive immune response. Cancer Res 72(13):3153-62, 2012. e-Pub 2012. PMID: 22564522.
Joseph RW, Bayraktar UD, Kim TK, St John LS, Popat U, Khalili J, Molldrem JJ, Wieder ED, Komanduri KV. Vitamin D receptor upregulation in alloreactive human T cells. Hum Immunol 73(7):693-8, 2012. e-Pub 2012. PMID: 22548720.
Wu RC, Liu S, Chacon JA, Wu S, Li Y, Sukhumalchandra P, Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi LG. Detection and characterization of a novel subset of CD8+CD57+ T-cells in metastatic melanoma with an incompletely-differentiated phenotype. Clin Cancer Res 18(9):2465-77, 2012. e-Pub 2012. PMID: 22307139.
Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, St John LS, Yang TH, Ruisaard K, Armistead PM, Mittendorf EA, He H, Qiao N, Rodriguez-Cruz T, Liang S, Clise-Dwyer K, Wieder ED, Lizee G, Lu S, Molldrem JJ. The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1. J Immunother 35(4):309-20, 2012. e-Pub 2012. PMID: 22495388.
Li H, Su X, Gallegos J, Lu Y, Ji Y, Molldrem JJ, Liang S. dsPIG: A tool to predict imprinted genes from the deep sequencing of whole transcriptomes. BMC Bioinformatics 13(271):271, 2012. e-Pub 2012. PMID: 23083219.
Decker WK, Shah N, Xing D, Lapushin R, Li S, Robinson SN, Yang H, Parmar S, Halpert MM, Keating MJ, Gribben JG, Molldrem JJ, Shpall EJ, Wierda WG. Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC. PLoS One 7(12):e51390, 2012. e-Pub 2012. PMID: 23284688.
Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, Aung F, Rondon G, Molldrem JJ, Korbling M, Shpall EJ, de Lima M, Champlin RE, Fernandez-Vina M. Donor-specific anti-HLA antibodies and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 118(22):5957-64, 2011. e-Pub 2011. PMID: 21967975.
Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A 108(46):18637-42, 2011. e-Pub 2011. PMID: 22049339.
Weng J, Cha SC, Matsueda S, Alatrash G, Popescu MS, Yi Q, Molldrem JJ, Wang M, Neelapu SS, Kwak LW. Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. Clin Cancer Res 17(18):5945-52, 2011. e-Pub 2011. PMID: 21813633.
Tao RH, Berkova Z, Wise JF, Rezaeian AH, Daniluk U, Ao X, Hawke DH, Karp JE, Lin HK, Molldrem JJ, Samaniego F. PMLRAR{alpha} binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo. Blood 118(11):3107-18, 2011. e-Pub 2011. PMID: 21803845.
Lacey SF, La Rosa C, Kaltcheva T, Srivastava T, Seidel A, Zhou W, Rawal R, Hagen K, Krishnan A, Longmate J, Andersson HA, St John L, Bhatia R, Pullarkat V, Forman SJ, Cooper LJ, Molldrem J, Diamond DJ. Characterization of immunological properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. Blood 118(8):2159-69, 2011. e-Pub 2011. PMID: 21719601.
Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J, McIntyre BW, Ma Q, Li D, St John L, Clise-Dwyer K, Molldrem JJ. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 117(16):4262-72, 2011. e-Pub 2011. PMID: 21296998.
Alatrash G, Molldrem JJ. Vaccines as consolidation therapy for myeloid leukemia. Expert Rev Hematol 4(1):37-50, 2011. e-Pub 2011. PMID: 21322777.
Armistead PM, Liang S, Li H, Lu S, Van Bergen CA, Alatrash G, St John L, Hunsucker SA, Sarantopoulos S, Falkenburg JH, Molldrem JJ. Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. PLoS One 6(8):e23217, 2011. e-Pub 2011. PMID: 21858034.
Ma Q, Wang C, Jones D, Quintanilla KE, Li D, Wang Y, Wieder ED, Clise-Dwyer K, Alatrash G, Mj Y, Munsell MF, Lu S, Qazilbash MH, Molldrem JJ. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy 12(8):1056-62, 2010. e-Pub 2010. PMID: 20735170.
Li D, Li Y, Hernandez JA, Patenia R, Kim TK, Khalili J, Dougherty MC, Hanley PJ, Bollard CM, Komanduri KV, Hwu P, Champlin RE, Radvanyi LG, Molldrem JJ, Ma Q. Lovastatin inhibits T-cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs. J Immunother 33(9):975-82, 2010. e-Pub 2010. PMID: 20948439.
Carreño R, Brown WS, Li D, Hernandez JA, Wang Y, Kim TK, Craft JW, Komanduri KV, Radvanyi LG, Hwu P, Molldrem JJ, Legge GB, McIntyre BW, Ma Q. 2E8 binds to the high-affinity I-domain in a metal ion dependent manner: a second generation monoclonal antibody selectively targeting activated LFA-1. J Biol Chem 285(43):32860-8, 2010. e-Pub 2010. PMID: 20724473.
Molldrem JJ, Alatrash G. Immune rage against MAGE unleashed. Blood 116(11):1824-5, 2010. e-Pub 2010. PMID: 20847207.
Armistead PM, Wieder E, Akande O, Alatrash G, Quintanilla K, Liang S, Molldrem J. Cyclic neutropenia associated with T cell immunity to granulocyte proteases and a double de novo mutation in GFI1, a transcriptional regulator of ELANE. Br J Haematol 150(6):716-719, 2010. e-Pub 2010. PMID: 20560965.
Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH. NCI 1st International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft versus tumor effects: state of the science. Biol Blood Marrow Transplant 16(6):709-28, 2010. e-Pub 2010. PMID: 20227509.
Palmer LA, Sale GE, Balogun JI, Li D, Jones D, Molldrem JJ, Storb RF, Ma Q. Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease. Biol Blood Marrow Transplant 16(3):311-9, 2010. e-Pub 2010. PMID: 20025985.
Kanodia S, Wieder E, Lu S, Talpaz M, Alatrash G, Clise-Dwyer K, Molldrem JJ. PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One 5(7):e11770, 2010. e-Pub 2010. PMID: 20668669.
Wang Y, Li D, Jones D, Bassett R, Sale GE, Khalili J, Komanduri KV, Couriel DR, Champlin RE, Molldrem JJ, Ma Q. Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation. Biol Blood Marrow Transplant 15(12):1513-22, 2009. e-Pub 2009. PMID: 19896074.
Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, Gee AP, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. Functionally active virus-specific T-cells that target CMV, adenovirus and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 114(19):1958-67, 2009. e-Pub 2009. PMID: 19443656.
Li D, Molldrem JJ, Ma Q. LFA-1 regulates CD8+ T cell activation via TCR-mediated and LFA-1-mediated ERK1/2 signal pathways. J Biol Chem 284(31):21001-10, 2009. e-Pub 2009. PMID: 19483086.
Wang Y, Li D, Nurieva R, Yang J, Sen M, Carreño R, Lu S, McIntyre BW, Molldrem JJ, Legge GB, Ma Q. LFA-1 affinity regulation is necessary for the activation and proliferation of naive T cells. J Biol Chem 284(19):12645-53, 2009. e-Pub 2009. PMID: 19297325.
Sergeeva A, Ono Y, Rios R, Molldrem JJ. High titer autoantibodies to GM-CSF in patients with AML, CML, and MDS are associated with active disease. Leukemia 22(4):783-90, 2008. e-Pub 2008. PMID: 18216869.
Lee ST, Liu S, Radvanyi L, Sukhumalchandra P, Molldrem JJ, Wieder ED, Hwu P, Liu YJ, Kwak LW, Lizée G, Neelapu SS. A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones. J Immunol Methods 331(1-2):13-26, 2008. e-Pub 2008. PMID: 17959194.
Yang Y, Iwanaga K, Raso MG, Wislez M, Hanna AE, Wieder ED, Molldrem JJ, Wistuba II, Powis G, Demayo FJ, Kim CF, Kurie JM. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One 3(5):e2220, 2008. e-Pub 2008. PMID: 18493606.
Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I, Bryan SG, Kaur I, Martin S, Wieder ED, Worth L, Cooper LJ, Petropoulos D, Molldrem JJ, Champlin RE, Shpall EJ. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 110(13):4543-51, 2007. e-Pub 2007. PMID: 17671230.
Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 40(2):125-36, 2007. e-Pub 2007. PMID: 17530009.
Yao YG, Ogasawara Y, Kajigaya S, Molldrem JJ, Falcão RP, Pintão MC, McCoy JP, Rizzatti EG, Young NS. Mitochondrial DNA sequence variation in single cells from leukemia patients. Blood 109(2):756-762, 2007. e-Pub 2007. PMID: 16946307.
Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12(10):1160-6, 2006. e-Pub 2006. PMID: 16998485.
Bollard CM, Gottschalk S, Huls MH, Molldrem J, Przepiorka D, Rooney CM, Heslop HE. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma 47(5):837-42, 2006. e-Pub 2006. PMID: 16753867.
Ozdemir E, Molldrem JJ. Hookworm infection of sigmoid colon masquerading as graft-versus-host disease in an allogeneic stem cell transplant recipient after donor lymphocyte infusion for refractory acute promyelocytic leukemia. Bone Marrow Transplant 37(8):785-6, 2006. e-Pub 2006. PMID: 16501592.
Parmar S, Robinson SN, Komanduri K, St John L, Decker W, Xing D, Yang H, McMannis J, Champlin R, de Lima M, Molldrem J, Rieber A, Bonyhadi M, Berenson R, Shpall EJ. Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. Cytotherapy 8(2):149-57, 2006. e-Pub 2006. PMID: 16698688.
Molldrem JJ. Vaccinating transplant recipients. Nat Med 11(11):1162-3, 2005. e-Pub 2005. PMID: 16270072.
Rangel R, McKeller MR, Sims-Mourtada JC, Kashi C, Cain K, Wieder ED, Molldrem JJ, Pham LV, Ford RJ, Yotnda P, Guret C, Francés V, Martinez-Valdez H. Assembly of the kappa preB receptor requires a V kappa-like protein encoded by a germline transcript. J Biol Chem 280(18):17807-14, 2005. e-Pub 2005. PMID: 15757909.
Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 11(2):108-14, 2005. e-Pub 2005. PMID: 15682071.
Martins SL, St John LS, Champlin RE, Wieder ED, McMannis J, Molldrem JJ, Komanduri KV. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood 104(12):3429-36, 2004. e-Pub 2004. PMID: 15284108.
Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D, McMannis J, Champlin RE, Molldrem JJ, Komanduri KV. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood 103(3):1140-6, 2004. e-Pub 2004. PMID: 12907445.
Battiwalla M, Melenhorst J, Saunthararajah Y, Nakamura R, Molldrem J, Young NS, Barrett AJ. HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders. Br J Haematol 123(3):449-53, 2003. e-Pub 2003. PMID: 14617004.
Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED, Bollard C, Michalek J, Ghetie V, Heslop HE, Molldrem JJ, Rooney CM, Schlinder J, Vitetta E, Brenner MK. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 102, Erratum 104(6):2292-9, 2003. e-Pub 2003. PMID: 12763937.
Dang NH, Aytac U, Sato K, O'Brien S, Melenhorst J, Morimoto C, Barrett AJ, Molldrem JJ. T-large granular lymphocyte lymphoproliferative disorder: Expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition. Br J Haematol 121(6):857-65, 2003. e-Pub 2003. PMID: 12786796.
Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S, Wang C, Davis MM. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 111(5):639-47, 2003. e-Pub 2003. PMID: 12618518.
Melenhorst JJ, Eniafe R, Follmann D, Molldrem J, Kirby M, El Ouriaghli F, Barrett AJ. T-cell large granular lymphocyte leukemia is characterized by massive TCRBV-restricted clonal CD8 expansion and a generalized overexpression of the effector cell marker CD57. Hematol J 4(1):18-25, 2003. e-Pub 2003. PMID: 12692516.
Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 100(10):3639-45, 2002. e-Pub 2002. PMID: 12393644.
Ozdemir E, St John LS, Gillespie G, Rowland-Jones S, Champlin RE, Molldrem JJ, Komanduri KV. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 100(10):3690-7, 2002. e-Pub 2002. PMID: 12393402.
Saunthararajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, Maciejewski JP, Simonis T, Molldrem J, Young NS, Barrett AJ. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100(5):1570-4, 2002. e-Pub 2002. PMID: 12176872.
Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, Molldrem J, Ueno NT, Donato M, Korbling M, Gajewski J, Alexanian R, Champlin R. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 30(6):367-73, 2002. e-Pub 2002. PMID: 12235521.
Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C, Liu J, Nakamura R, Young NS, Barrett AJ. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 137(3):156-63, 2002. e-Pub 2002. PMID: 12160363.
Guo W, Chan AP, Liang H, Wieder ED, Molldrem JJ, Etkin LD, Nagarajan L. A human mix-like homeobox gene MIXL shows functional similarity to xenopus mix.1. Blood 100(1):89-95, 2002. e-Pub 2002. PMID: 12070013.
Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D, Rick ME. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98(4):979-87, 2001. e-Pub 2001. PMID: 11493442.
Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97(3):631-7, 2001. e-Pub 2001. PMID: 11157478.
Saunthararajah Y, Molldrem JL, Rivera M, Williams A, Stetler-Stevenson M, Sorbara L, Young NS, Barrett JA. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: Clinical and pathophysiological features. Br J Haematol 112(1):195-200, 2001. e-Pub 2001. PMID: 11167802.
Shimoni A, Körbling M, Champlin R, Molldrem J. Cryofibrinogenemia and skin necrosis in a patient with diffuse large cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 26(12):1343-5, 2000. e-Pub 2000. PMID: 11223976.
Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6(9):1018-23, 2000. e-Pub 2000. PMID: 10973322.
Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Levenback C, Wolf J, Champlin RE. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant 25(11):1137-40, 2000. e-Pub 2000. PMID: 10849525.
Raptis A, Mavroudis D, Suffredini A, Molldrem J, Rhee FV, Childs R, Phang S, Barrett A. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients. Bone Marrow Transplant 24(8):879-83, 1999. e-Pub 1999. PMID: 10516700.
Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 59(11):2675-81, 1999. e-Pub 1999. PMID: 10363991.
Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Körbling M, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 10(5):527-32, 1999. e-Pub 1999. PMID: 10416001.
Hensel N, Agarwala V, Jiang YZ, Mavroudis D, Molldrem J, Barrett AJ. A technique for dual determination of cytotoxic and helper lymphocyte precursor frequency by a miniaturized dye release method. Bone Marrow Transplant 23(1):71-8, 1999. e-Pub 1999. PMID: 10037053.
Clave E, Molldrem J, Hensel N, Raptis A, Barrett AJ. Donor-recipient polymorphism of the proteinase 3 gene: A potential target for T-cell alloresponses to myeloid leukemia. J Immunother 22(1):1-6, 1999. e-Pub 1999. PMID: 9924693.
Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 102(5):1314-22, 1998. e-Pub 1998. PMID: 9753062.
Raptis A, Clave E, Mavroudis D, Molldrem J, Van Rhee F, Barrett AJ. Polymorphism in CD33 and CD34 genes: A source of minor histocompatibility antigens on haemopoietic progenitor cells?. Br J Haematol 102(5):1354-8, 1998. e-Pub 1998. PMID: 9753070.
Mavroudis DA, Dermime S, Molldrem J, Jiang YZ, Raptis A, van Rhee F, Hensel N, Fellowes V, Eliopoulos G, Barrett AJ. Specific depletion of alloreactive T cells in HLA-identical siblings: A method for separating graft-versus-host and graft-versus-leukaemia reactions. Br J Haematol 101(3):565-70, 1998. e-Pub 1998. PMID: 9633903.
Barrett AJ, Mavroudis D, Tisdale J, Molldrem J, Clave E, Dunbar C, Cottler-Fox M, Phang S, Carter C, Okunnieff P, Young NS, Read EJ. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 21(6):543-51, 1998. e-Pub 1998. PMID: 9543057.
Mavroudis DA, Read EJ, Molldrem J, Raptis A, Plante M, Carter CS, Phang S, Dunbar CE, Barrett AJ. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia. Bone Marrow Transplant 21(5):431-40, 1998. e-Pub 1998. PMID: 9535034.
Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 99(3):699-705, 1997. e-Pub 1997. PMID: 9401087.
Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N, Agarwala V, Barrett AJ. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 90(7):2529-34, 1997. e-Pub 1997. PMID: 9326217.
Jiang YZ, Mavroudis DA, Dermime S, Molldrem J, Hensel NF, Barrett AJ. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: Implications for separating graft-versus-leukemia effect from graft-versus-host disease. Bone Marrow Transplant 19(9):899-903, 1997. e-Pub 1997. PMID: 9156263.
Dermime S, Mavroudis D, Jiang YZ, Hensel N, Molldrem J, Barrett AJ. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant 19(10):989-99, 1997. e-Pub 1997. PMID: 9169643.
Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N, Fukushima P, Barrett AJ. Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88(7):2450-7, 1996. e-Pub 1996. PMID: 8839835.
Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C, Yu M, Dunbar C, Barrett J. CD34+ cell dose predicts survival, post-transplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 88(8):3223-9, 1996. e-Pub 1996. PMID: 8874224.
Jiang YZ, Mavroudis D, Dermime S, Hensel N, Couriel D, Molldrem J, Barrett AJ. Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol 93(3):606-12, 1996. e-Pub 1996. PMID: 8652381.
Jiang YZ, Couriel D, Mavroudis DA, Lewalle P, Malkovska V, Hensel NF, Dermime S, Molldrem J, Barrett AJ. Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A. Immunology 87(3):481-6, 1996. e-Pub 1996. PMID: 8778037.

Invited Articles

Molldrem JJ. What T cells see in WT-1. Blood 120(8):1540-1, 2012. e-Pub 2012. PMID: 22918422.
Molldrem JJ. Preparing basic and translational grant proposals: Thoughts from the trenches. Hematology Am Soc Hematol Educ Program 2010:181-4, 2010. e-Pub 2010. PMID: 21239790.
Rusakiewicz S, Molldrem JJ. Immunotherapeutic peptide vaccination with leukemia-associated antigens. Curr Opin Immunol 18(5):599-604, 2006. e-Pub 2006. PMID: 16870418.
Molldrem JJ. Vaccination for leukemia. Biol Blood Marrow Transplant 12(1 Suppl 1):13-8, 2006. e-Pub 2006. PMID: 16399579.
Gale RP, Horowitz MM, Talpaz M, Scheinberg DA, Molldrem J, Li Z, Baccarani M, Goldman JM, Tura S. Immune therapy of chronic myelogenous leukemia. Leuk Res 29(5):583-6, 2005. e-Pub 2005. PMID: 15755511.
Molldrem JJ. PR1 peptide vaccine induces complete remissions in leukemia, Phase I study reports. Oncology News International, 2005. e-Pub 2005.
Kurbegov D, Molldrem JJ. Immunity to chronic myelogenous leukemia. Hematol Oncol Clin North Am 18(3):733-52, xi-xii, 2004. e-Pub 2004. PMID: 15271403.
Molldrem JJ. Immune modulation in MDS: Pathophysiology & treatment. ASCO Educational Book, American Society of Clinical Oncology, 2004. e-Pub 2004.
Lu S, Wieder E, Komanduri K, Ma Q, Molldrem JJ. Vaccines in leukemia. Adv Pharmacol 51:255-70, 2004. e-Pub 2004. PMID: 15464913.
List AF, Molldrem J, Sanders JE. Prognosis and treatment of myelodysplastic syndromes. ASCO Educational Book, American Society of Clinical Oncology, 2004. e-Pub 2004.
Lu S, Wieder E, Komanduri K, Ma Q, Molldrem JJ. Vaccines in leukemia. Adv Pharmacol 51:255-70, 2004. e-Pub 2004. PMID: 15464913.
Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology Am Soc Hematol Educ Program:331-49, 2003. e-Pub 2003. PMID: 14633789.
Molldrem JJ, Komanduri K, Wieder E. Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions. Curr Opin Hematol 9(6):503-8, 2002. e-Pub 2002. PMID: 12394172.
Molldrem JJ. Non-myeloablative stem cell transplants as a platform for antigen-specific immunotherapy. Highlight Reports, 2001 Tandem BMT Meetings:8-11, 2001. e-Pub 2001.
Molldrem JJ. Allogeneic immunotherapy and unrelated stem cell grafting. ASCO Spring Educational Book, American Society of Clinical Oncologists:610-15, 2001. e-Pub 2001.

Review Articles

Sergueeva, A, Leung, WK, St John, L, Molldrem, JJ. Anti-GM-CSF autoantibodies in myeloid leukemias. Best Practice and Research: Clinical Haematology 38(1), 2025. e-Pub 2025. PMID: 40274339.
Sergeeva A, Leung WK, St John L, Molldrem JJ. Anti-GM-CSF autoantibodies in myeloid leukemias. Best Pract Res Clin Haematol 38(1):101611, 2025. e-Pub 2025. PMID: 40274339.
Molldrem, JJ, Zha, D. Unlocking Intracellular Oncology Targets. Cancers 16(22), 2024. e-Pub 2024. PMID: 39594730.
Kannan S, Vedia RA, Molldrem JJ. The immunobiology of myelodysplastic neoplasms: a mini-review. Front Immunol 15:1419807, 2024. e-Pub 2024. PMID: 39355256.
Sizova O, John LS, Ma Q, Molldrem JJ. Multi-faceted role of LRP1 in the immune system. Front Immunol 14:1166189, 2023. e-Pub 2023. PMID: 37020553.
Alatrash G, Molldrem JJ. Immunotherapy of AML. Cancer Treat Res 145:237-55, 2010. e-Pub 2010. PMID: 20306255.
Molldrem J, Riddell S. Understanding and enhancing the graft-versus-leukemia effect after hematopoetic stem cell transplantation. Cancer Treat Res 144:1-22, 2009. e-Pub 2009. PMID: 19779869.
Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W. Display technologies: application for the discovery of drug and gene delivery agents. Adv Drug Deliv Rev 58(15):1622-54, 2006. e-Pub 2006. PMID: 17123658.
Kondo Y, Molldrem JJ. Immune-induced cytopenia: bone marrow failure syndrome. Curr Hematol Rep 3(3):178-83, 2004. e-Pub 2004. PMID: 15087065.
Champlin R, Khouri I, Anderlini P, De Lima M, Hosing C, McMannis J, Molldrem J, Ueno N, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Williston Park) 17(1):94-100; discussion 103-7, 2003. e-Pub 2003. PMID: 12599934.
Molldrem JJ, Kant S, Jiang W, Lu S. The basis of T-cell-mediated immunity to chronic myelogenous leukemia. Oncogene 21(56):8668-73, 2002. e-Pub 2002. PMID: 12476312.
Kochenderfer JN, Molldrem JJ. Leukemia vaccines. Curr Oncol Rep 3(3):193-200, 2001. e-Pub 2001. PMID: 11296128.
Champlin R, Khouri I, Anderlini P, Gajewski J, Kornblau S, Molldrem J, Shimoni A, Ueno N, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant 27 Suppl 2:S13-22, 2001. e-Pub 2001. PMID: 11436116.
Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J, Ueno N, Giralt S, Anderlini P. Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111(1):18-29, 2000. e-Pub 2000. PMID: 11091179.
Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?. Semin Hematol 37(1):15-29, 2000. e-Pub 2000. PMID: 10676908.
Champlin R, Khouri I, Kornblau S, Marini F, Anderlini P, Ueno NT, Molldrem J, Giralt S. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol Oncol Clin North Am 13(5):1041-57, vii-viii, 1999. e-Pub 1999. PMID: 10553260.
Champlin R, Khouri I, Kornblau S, Molldrem J, Giralt S. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol 11(2):87-95, 1999. e-Pub 1999. PMID: 10188072.
Molldrem J, Wilson WH. Infusional chemotherapy for non-Hodgkin's lymphoma. Review. Cancer Invest 15(5):465-74, 1997. e-Pub 1997. PMID: 9316629.

Editorials

Molldrem JJ, Lu S. A GVHD kill switch helps immune reconstitution. Blood 123(25):3849-50, 2014. PMID: 24948621.
Molldrem JJ. What T-cells see in WT-1. Blood 120(8):1540-1, 2012. PMID: 22918422.
Molldrem JJ. Antigen-specific lymphocyte therapies. Cytotherapy 4(4):315-6, 2002. PMID: 12396830.
Molldrem J. Immune therapy of AML. Cytotherapy 4(5):437-8, 2002. PMID: 12473216.

Abstracts

Gall V, Philips AV, Qioa N, Dwyer KC, Perakis AA, Zhang M, Sukhumalchandra P, Molldrem JJ, Alatrash G, Mittendorf EA. Trastuzumab increases uptake and cross-presentation of HER2-derived antigens by dendritic cells. Cancer Research, Proceedings: AACR 107th Annual Meeting 2016, 2016. e-Pub 2016.
Gall V, Philips AV, Chawla A, Qiao N, St John LS, Sukhumalchandra P, Zhang M, Molldrem JJ, Alatrash G, Mittendorf EA. Neutrophil elastase regulates PD-L1 expression in breast cancer. Cancer Research, Proceedings: AACR 107th Annual Meeting 2016, 2016. e-Pub 2016.
Garber HR, Beird H, Zhang J, Futreal A, Molldrem JJ. Subclonal evolution of chronic lymphocytic leukemia (CLL) after allogeneic T-cell immunotherapies. Keystone Symposia on Molecular and Cellular Biology, 2016. e-Pub 2016.
He H, Lu S, Tallis E, Garber HR, Ding X, Ruisaard KE, Salvado B, Woods MS, St John LS, Dwyer KC, Sergueeva A, Al-Atrash G, Sukhumalchandra P, Ma Q, Gianpietro D, Molldrem JJ. Engineering a TCR-like anti-PR1/HLA-A2 antibody scFv in a novel chimeric antigen receptor (CAR) to redirect T cells to eliminate myeloid leukemia. Biology of Blood and Marrow Transplantation, 2016. e-Pub 2016.
Sergeeva A, Sang M, Ruisaard K, St John L, Clise-Dwyer K, Lu S, Kerros C, Rodriguez-Cruz, Lizee G, Molldrem JJ. Humanized anti-PR1/HLA-A2 antibody h8F4 induces apoptosis of human acute myeloid leukemia. Keystone Symposia on Molecular and Cellular Biology, 2016. e-Pub 2016.
Herrmann A, Im J, Lu S, Sergeeva A, Molldrem JJ. Development of a novel TCR-like Bi-specific T cell engager targeting PR1/HLA-A2 leukemia antigen. Cancer Research, Proceedings: AACR 107th Annual Meeting 2016, 2016. e-Pub 2016.
Li D, Patenia R, Nurieva R, Molldrem JJ, Champlin RE, Ma Q. Ibrutinib treatment modulates T cell activation and polarization in immune response. Blood (Poster) 126(23):3435, 2015. e-Pub 2015.
Alousi AM, Bassett R, Chen J, Overman BJ, Hosing CM, Popat UR, Shpall EJ, Nieto Y, Qazilbash MH, Khouri IF, Kebriaei P, Ahmed S, Shah N, Rezvani K, Kondo K, Ciurea SO, Hymes SR, Newmann JL, Molldrem JJ, Plair TR, Champlin RE. A Bayesian, Phase II randomized trial of extracorporeal photopheresis (ECP) plus steroids versus steroids-alone in patients with newly diagnosed acute graft vs. host disease (GVHD): The addition of ECP improves GVHD response and the ability to taper steroids. Blood (Oral Abstract) 126(23):854, 2015. e-Pub 2015.
Li D, Patenia R, Cruz MA, Molldrem JJ, Champlin RE, Ma Q. Intermediate filament (IF) protein vimentin regulates T cell mediated immune response in GVHD. Blood (Poster) 126(23):3079, 2015. e-Pub 2015.
Logan AC, Herrera AF, Ryan CE, Rezvani AR, Kong KA, Faham M, Alatrash G, Molldrem JJ, Sargent RL, Alyea EP, HO VT, Brown JR, Ritz J, Miklos DB. Molecular remission one year following reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia predicts relapse-free and overall survival: A multi-institutional landmark analysis. Blood (Poster) 126(23):4340, 2015. e-Pub 2015.
Alatrash G, Zhang M, Qiao N, Sukhumalchandra P, Zope M, Philips AV, Perakis A, St John L, Khouri MR, Gall V, Dwyer KC, Polan J, Molldrem JJ, Shpall EJ, Mittendorf EA. Fucosylated antigen-specific cytotoxic T lymphocytes demonstrate enhanced killing of leukemia targets. Blood (Poster) 126(23):18888, 2015. e-Pub 2015.
Peters HL, Tripathi SC, Katayama H, Kerros C, Perakis A, St John L, Alatrash G, Hanash S, Molldrem JJ. Neutrophil elastase induces post-transcriptional increase of surface MHC class I expression on lung cancer cells (Poster). Cancer Research, Proceedings: AACR 106th Annual Meeting 2015, 2015. e-Pub 2015.
Kerros C, Tripathis SC, Philips AV, Alatrash G, Ruisaard KE, Dwyer KC, Mittendorf EA, Hanash S, Molldrem JJ. Characterization of neutrophil elastase uptake in breast cancer: Implications for immunotherapy (Poster). Cancer Research, Proceedings: AACR 106th Annual Meeting 2015, 2015. e-Pub 2015.
Garber HR, Beird H, Cao Y, Zhang J, Sargent R, Lin P, Seth S, Song X, Sun H, Mao X, St John L, Dwyer KC, Alatrash G, Futreal PA, Molldrem JJ. Long-term subclonal evolution of CLL from immune selective pressure after allogeneic stem cell transplant and donor lymphocyte infusion (Late Breakin Abstract - Poster). Cancer Research, Proceedings: AACR 106th Annual Meeting 2015, 2015. e-Pub 2015.
Im J, Cernosek A, Sergeeva A, Molldrem JJ, Lu S. Novel TCR-like bi-specific T cell engaging antibody targeting the PR1/HLA-A2 myeloid leukemia antigen. Blood (Poster Session) 124(21), 2014. e-Pub 2014.
Khouri IF, Anfossi S, Saliba RM, St John LS, Molldrem JJ, Reuben JM. Serum miRNA expression and allogeneic stem cell transplantation in patients with B chronic lymphocytic leukemia (CLL). Blood (Online Publication Only Abstracts) 124(21), 2014. e-Pub 2014.
Chen R, Malouf GG, Zhang J, Huang X, Weinstein JN, Spano JP, Molldrem JJ, Plunkett W, Su X. Genome-wide mapping and subtype classification of long non-coding RNA in acute myeloid leukemia. Blood (Poster Session) 124(21), 2014. e-Pub 2014.
Yang TH, St John LS, Dwyer KC, Ruisaard K, Alatrash G, Molldrem JJ. Inhibition of T cell proliferation by granulocyte membrane-associated proteinase 3 is reversed by blocking the interaction of calreticulin with LRP on T cells. Blood (Poster Session) 124(21), 2014. e-Pub 2014.
Alatrash G, Sukhumalchandra P, Zhang M, Kerros C, Sergeeva A, Cernosek A, Jakher H, Zope M, Patenia R, St John L, Perakis A, Dwyer KC, Young KH, Weng J, Lu S, Mittendorf EA, Kwak LW, Ma Q, Molldrem JJ. PR1 is cross-presented by multiple myeloma cells in patients and renders multiple myeloma susceptible to PR1-CTL and anti-PR1/HLA-A2 antibody. Blood (Poster Session) 124(21), 2014. e-Pub 2014.
Alatrash G, Zhang M, Sukhumalchandra P, Qiu Y, Talukder AH, Senyukov V, St John LS, He H, Sergeeva A, Roszik J, Dwyer KC, Lu S, Ma Q, Mittendorf EA, Lee D, Hawke DH, Lizee G, Molldrem JJ, Kornblau SM. Cathepsin G Is broadly expressed by AML and us an effective immunotherapeutic target against AML in vivo. Blood (Poster Session) 124(21), 2014. e-Pub 2014.
Chawla A, Philips AV, Qiao N, Sukhumalchandra P, Kerros C, Alatrash G, Molldrem JJ, Mottendorf EA. Neutrophil elastase enhances adaptive immunity via increase of peptide presentation and downregulation of T cell inhibitory molecules. Cancer Research, Proceedings: AACR Annual Meeting 2014, 2014. e-Pub 2014.
Herrmann A, Im JS, Lu S, Molldrem JJ. Bi-specific T-cell engaging antibody activates T-cells to target the tumor associated antigen PR1. Cancer Research, Proceedings: AACR Annual Meeting 2014, 2014. e-Pub 2014.
Wan L, St John LS, He H, Clise-Dwyer K, Cooper LJ, Shpall EJ, Bollard CM, Molldrem JJ. PR1-specific cytotoxic T lymphocytes expanded from cord blood are functional in vitro. The Journal of Immunology 192(205.3), 2014. e-Pub 2014.
Chawla A, Philips AV, Qiao N, Sukhumalchandra P, Kerros C, Molldrem J, Alatrash G, Mittendorf EA. Neutrophil elastase uptake by breast cancer increases anti-tumor adaptive immune response by upregulation of HLA class I molecules. Annals of Surgical Oncology 21(S51), 2014. e-Pub 2014.
Dharamsiri U, Hunsucker SA, Vincent BG, Wu M, Collins EJ, Liang S, Molldrem JJ, Armistead PM. UNC-GRK4-1: an allele specific cancer testis antigen identified through genomic screening. Blood (Poster Session) 122(21), 2013. e-Pub 2013.
Savaria A, Khoder A, Alsuliman A, Chew C, Sekine T, Cooper N, de Lavallade H, Muftuoglu M, Yvon E, Hamdi A, Alousi A, St John LS, Marin D, Stringaris K, Liu E, Molldrem JJ, Shah N, Parmar S, McNiece IK, Champlin RE, Spall EJ, Rezvani K. B cell with regulatory function are enriched within transitional and IgM memory B cell subsets in healthy donors but are reduced and functionally impaired in patients with chronic graft-versus-host disease. Blood (Poster Session) 122(21), 2013. e-Pub 2013.
Oran B, Hosing CM, Kebriaei P, Rezvani K, Parmar S, Shah N, Bollard CM, Molldrem JJ, Nieto Y, Andersson BS, Alousi A, Jones RB, Cooper LJN, Qazilbash MH, Bashir Q, Ahmed S, Bosque D, Chen J, McCarty J, Rondon G, Munsell M, McNiece IK, Kaur I, Kaur I, Yvon E, Annadale K, Olchesky S, de Lima MJ, Champlin RE, Miller L, Paradiso L, Koh L, Zweidler-McKay PA, Shpall EJ. Ex vivo fucosylation of cord blood accelerates neutrophil and platelet engraftment. Blood (Oral Session) 122(21), 2013. e-Pub 2013.
St John L, He H, Ruisaard K, Ma Q, Shpall E, Clise-Dwyer K, Molldrem J. PR1-CTL directly sort-purified from umbilical cord blood lymphocytes reduce human AML in vivo. The Journal of Immunology (Poster session) 190, 2013. e-Pub 2013.
Vincent BG, Singh D, Wu M, Hunsucker SA, Alatrash G, Ruisaard K, Sukhumalchandra P, Clise-Dwyer K, Serody JS, Prins JF, Molldrem JJ, Armistead PM. RNA-seq expression profiling of AML stem cells reveals differential expression of lineage differentiation markers and novel splice variants. Blood (Poster Session) 120, 2012. e-Pub 2012.
Alatrash G, Sukhumalchandra P, Zhang M, Sergeeva A, Jakher H, Weng J, St John LS, Ruisaard K, Clise-Dwyer K, Lu S, Molldrem JJ. Multiple myeloma cross-presents neutrophil elastase and proteinase 3 and becomes susceptible to PR1-targeting immunotherapy. Blood (Online Publication) 120, 2012. e-Pub 2012.
Yang TH, Clise-Dwyer K, St John LS, Alatrash G, Ruisaard K, Lu S, Molldrem JJ. Membrane-associated proteinase 3 on granulocytes and myeloid leukemia mediates reversible inhibition of T cell proliferation associated with altered ZAP70 and ERK signaling. Blood (Poster Session) 120, 2012. e-Pub 2012.
St John L, Clise-Dwyer K, Patenia R, Sergeeva A, He H, Bollard C, Shpall E, Lu S, Ma Q, Molldrem J. A high frequency of naive PR1-specific CD8+ T cells in umbilical cord blood and fetal thymus suggest incomplete central tolerance to the hematopoietic self-antigen PR1. The Journal of Immunology 188, 2012. e-Pub 2012.
Yang TH, Clise-Dwyer K, Alatrash G, Ruisaard K, Liang S, Molldrem JJ. Membrane-associated proteinase 3 on granulocytes and myeloid leukemia mediates reversible inhibition of T cell proliferation. Blood 18(21), 2011. e-Pub 2011.
Zhang M, Sukhumalchandra P, Enyenihi A, St John LS, Hunsucker S, Ruisaard K, Al Atrache Z, Ropp PA, Rodriguez-Cruz T, Mittendorf E, Lizee G, Clise-Dwyer K, Lu S, Glish GL, Molldrem JJ, Armistead PM, Alatrash G. A novel HLA-A2 restricted peptide derived from cathepsin G is an effective immunotherapeutic target for myeloid leukemia. Blood 18(21), 2011. e-Pub 2011.
Samaniego F, Berkova Z, Wise JF, Kerros C, Hawke DH, Je K, Lin HK, Molldrem JJ, Tao RH. PML and PMLRARα interact with Fas to regulate Fas-mediated apoptosis in vivo. Blood 18(21), 2011. e-Pub 2011.
Sergeeva A, He H, Ruisaard K, Clise-Dwyer K, St John LS, Patenia R, Sukhumalchandra P, Alatrash G, Decker WK, Shpall EJ, You MJ, Ma Q, Molldrem JJ. Treatment with 8F4, an anti-PR1/HLA-A2 T cell receptor-like antibody, reduces established acute myeloid leukemia and eliminates leukemia stem cells in mice. Blood 18(21), 2011. e-Pub 2011.
Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, Quintanilla, K, Armistead P, He H, Rodrirquez-Cruz T, Clise-Dwyer K, Wieder E, Lizee G, Lu S, Molldrem JJ. Peripheral tolerance to PR1 is maintained after uptake of soluble proteinase-3 and neutrophil elastase (Oral session). Blood 116(21), 2010. e-Pub 2010.
Yang TH, Alatrash G, Clise-Dwyer K, Quintanilla K, Lu S, Molldrem JJ. Proteinase 3 mediates enzyme-independent reversible inhibition of CD4 and CD8 T cell proliferation by blocking G1-S transition. Blood 116(21), 2010. e-Pub 2010.
St John LS, Clise-Dwyer K, Patenia R, Sergeeva A, Shpall EJ, Ma Q, Molldrem JJ. Surface expression of PR1 peptide on thymic dendritic cells does not eliminate PR1-specific CD8+ cells in umbilical cord blood (Oral Session). Blood 116(21), 2010. e-Pub 2010.
Alatrash G, Mittendorf E, Sergeeva A, Sukhumalchandra P, Qiao N, Quintanilla K, Zhang M, Lu S, Clise-Dwyer K, Molldrem JJ. Soluble inflammatory mediators proteinase-3 and neutrophil elastase are targeted by PR1-specific immunotherapy after cellular uptake and cross presentation of PR1 peptide by breast cancer cells. Blood 116(21), 2010. e-Pub 2010.
Mittendorf E, Alatrash G, Qiao N, Sukhumalchandra P, Lu S, Quintanilla K, Clise-Dwyer K, Molldrem JJ. Cellular uptake of soluble neutrophil elastase increases cyclin E (CCNE) isoform expression and significantly augments susceptibility of breast cancer cells to cytolysis by CCNE-specific cytotoxic T lymphocytes. Blood 116(21), 2010. e-Pub 2010.
Li D, Li H, Liang S, Molldrem J, Ma Q. Genome-wide transcription profiling identifies the mechanismis of LFA-1 contributing to CD8+ T cell activation and immune signal network. The Journal of Immunology 184, 2010. e-Pub 2010.
Diamond DJ, Zhou W, Srivastava T, Rawal R, Hagan K, Andersson HA, Cooper LJN, Molldrem JJ, Lacey SF. Breaking immune tolerance to granule proteases with full-length antigen vaccine in humanized transgenic mice reveals alternative antigen processing and immunodominance heirarchy applicable to clinical immunotherapy. Blood 114(22), 2009. e-Pub 2009.
He H, Ishiyama K, Alatrash G, Kondo Y, Lu S, Molldrem JJ. T-cell immunity to two HLA-A2-restricted self-determinants of cyclin E may contribute to remission after stem cell transplantation (Oral session). Blood 114(22), 2009. e-Pub 2009.
Sergeeva A, Alatrash G, Clise-Dwyer K, Quintanilla KE, Lu S, Ma Q, Li D, Wang Y, You MJ, Molldrem JJ. Anti-PR1/HLA-A2 antibody (8F4, A TCR-Mimic) mediates specific lysis of AML stem cells but not normal hematopoietic stem cells (Oral session). Blood 114(22), 2009. e-Pub 2009.
Hanley P, Savoldo B, Cruz C, Leen A, Molldrem J, Liu H, Gee AP, Heslop HE, Dotti G, Rodgers J, Rooney CM, Brenner MK, Shpall EJ, Bollard CM. Cytotoxic T lymphocytes (CTL) specific for CMV, adenovirus, and EBV can be generated from naive T cells for adoptive immunotherapy (Oral session). Blood 114(22), 2009. e-Pub 2009.
Li D, Li H, Liang S, Molldrem JJ, Ma Q. LFA-1 regulates CD8 + T cell activation and immune signal network. Blood 114(22), 2009. e-Pub 2009.
Ma Q, Li D, Molldrem JJ. LFA-1 regulates CD8+ T cell activation through both TCR-mediated and LFA-1-mediated Erk1/2 signal pathways. The Journal of Immunology 182, 2009. e-Pub 2009.
Hanley P, Savoldo B, Cruz CR, Leen AM, Molldrem JJ, Liu H, Gee AP, Heslop HE, Dotti G, Shpall EJ, Bollard CM. Cytotoxic T lymphocytes (CTL) specific for adenovirus and CMV can be generated from umbilical cord blood for adoptive immunotherapy. Biology of Blood and Marrow Transplantation 15(2):Supplement 1, pages 17-18, 2009. e-Pub 2009.
de Lima M, McNiece I, McMannis J, Hosing C, Kebraei P, Komanduri K, Worth L, Staba S, Cooper L, Petropolous D, Lee D, Jones R, Nieto Y, Andersson B, Korbling M, Alousi A, Qazilbash M, Popat U, Khouri I, Bollard C, Leen A, Rondon G, Molldrem J, Champlin R, Simmons P, Shpall E. Double cord blood transplantation (CBT) with ex-vivo expansion (EXP) of one unit utilizing a mesenchymal stromal cell (MSC) platform. Biology of Blood and Marrow Transplantation 15(2):Supplement 1, pages 47-48, 2009. e-Pub 2009.
Quintas-Cardama A, Kantarjian HM, Rios R, Wieder ED, Molldrem JJ, Cortes J. Randomized phase II study of proteinase 3-derived PR1 peptide vaccine and GM-CSF with or without PEG-interferon ALFA-2B to eradicate minimal residual disease in chronic myeloid leukemia. Blood 112(11):1104, 2008. e-Pub 2008.
Bollard CM, Hanley P, Cruz CR, Leen AM, Molldrem JJ, Liu H, Gee AP, Heslop HE, Dotti G, Savoldo B, Shpall EJ. Cytotoxic T lymphocytes (CTL) specific for adenovirus and CMV can be generated from umbilical cord blood for adoptive immunotherapy. Blood 112(11):1201, 2008. e-Pub 2008.
Khalili JS, Saliba RM, St John L, Alousi A, Wieder ED, De Lima M, Champlin R, Molldrem JJ, Shpall EJ, McMannis J, Komanduri KV. Regulatory and naïve T cells in unmanipulated donor grafts are not associated with acute graft vs host disease in matched sibling transplants for AML. Blood 112(11):267, 2008. e-Pub 2008.
Yang TH, Quintanilla KE, Cortez AM, Molldrem JJ. Proteinase 3 mediates direct inhibition of CD4 and CD8 T lymphocyte proliferation by inducing enzyme-independent G0/G1 cell cycle arrest (Publication only). Blood 112(11), 2008. e-Pub 2008.
Armistead P, Liang S, Lu S, van Bergen CAM, Falkenburg JHF, Molldrem JJ. Genomics as a tool for antigen discovery in allogeneic stem cell transplantation: Identification of the minor antigen T4A through donor/patient polymorphism disparities. Blood 112(11):1332, 2008. e-Pub 2008.
Sergeeva A, Lu S, Wygant JN, Alatrash G, Quintanilla K, Molldrem JJ. Direct visualization of PR1/HLA-A2 on the membrane of HLAA2+ CD13+CD33+ myeloid leukemia blasts by a novel monoclonal antibody. Blood 112(11):884, 2008. e-Pub 2008.
Alatrash G, Vence LM, Woodward W, Ueno NT, Molldrem JJ. Leukemia-associated primary granule proteins (PGPs) elastase-2 and proteinase-3 are aberrantly expressed in solid tumors: a potential therapeutic target for PR1-directed immunotherapy (Publication only). Blood 112(11), 2008. e-Pub 2008.
Joseph RW, Kim TK, St John L, Khalili J, Popat UR, Champlin RE, Molldrem JJ, Wieder E, Komanduri K. Demonstration of a direct immunomodulatory role for vitamin D in human T cells using flow cytometry. Blood 112(11):894, 2008. e-Pub 2008.
Quintas-Cardama A, Kantarjian HM, Wieder E, Molldrem J, Cortes JE. Randomized phase II study of proteinase 3-derived PR1 vaccine and GM-CSF with or without peg-interferon alfa-2b to eradicate minimal residual disease in chronic myeloid leukemia. Journal of Clinical Oncology 26(May 20 Supplement), 2008. e-Pub 2008.
Yang Y, Iwanaga K, Raso M, Wislez M, Hanna A, Wieder E, Molldrem J, Wistuba I, Powis G, Demay F, Kim C, Jurie J. Phosphatidylinosital 3-kinase stimulates the proliferation of bronchialveolar stem cells in mouse models of oncogenic K-ras-induced lung cancer. Cancer Research, Proceedings: AACR 98th Annual Meeting 2008, 2008. e-Pub 2008.
Alatrash G, Ono Y, Lu S, Sergeeva A, Sukhumalchandra P, Wang C, Wieder E, Molldrem JJ. Mistrafficking of primary granule proteins (PGPs) in leukemia simultaneously promotes PGP cross-priming and increases susceptibility to CTL killing (Oral Presentation). Cancer Research, Proceedings: AACR 98th Annual Meeting 2008, 2008. e-Pub 2008.
Bollard CM, Khalil M, Leen AM, Cruz CR, Decker W, Dotti G, Molldrem JJ, Rooney CM, Heslop HE, Shpall EJ. Cytotoxic T lymphocytes (CTL) specific for multiple viruses can be generated from umbilical cord blood for adoptive immunotherapy (Oral Presentation). Biology of Blood and Marrow Transplantation 14(2):Supplement 1, page 16, 2008. e-Pub 2008.
Khalili JS, Karandish S, Bryan S, Molldrem J, McMannis J, Komanduri KV. GCSF decreases CD4+CD25+CD127lo regulatory T cell proliferation index in stem cell donors (Poster). Biology of Blood and Marrow Transplantation 14(2):Supplement 1, page 130, 2008. e-Pub 2008.
Qazilbash MH, Wieder ED, Thall PF, Wang X, Rios R, Lu S, Kant S, Giralt S, Estey EH, Cortes J, Komanduri K, Champlin RE, Molldrem JJ. PR1 vaccine elicited immunological response after hematopoietic stem cell transplantation is associated with better clinical response and event-free survival. Blood 110(11), 2007. e-Pub 2007.
Qazilbash MH, Wieder ED, Thall PF, Wang X, Rios R, Lu S, Kant S, Giralt S, Estey EH, Cortes J, Komanduri K, Champlin RE, Molldrem JJ. PR1 peptide vaccine-induced immune response is associated with better event-free survival in patients with myeloid leukemia. Blood 110(11), 2007. e-Pub 2007.
Armistead PM, Wieder E, Akande O, Molldrem JJ. T-cell autoimmunity may contribute to neutropenia in a patient with cyclic neutropenia (CN) and double de-novo mutations in Gfi-1. Blood 110(11), 2007. e-Pub 2007.
Alatrash G, Ono Y, Lu S, Sergeeva A, Wang C, Wieder E, Molldrem JJ. Aberrant subcellular localization of azurophil granule proteins in myeloid leukemia favors peptide antigen presentation on MHC-I and susceptibility to killing by cytotoxic T lymphocytes. Blood 110(11), 2007. e-Pub 2007.
Sergeeva A, Ono Y, Molldrem JJ. Overexpressed circulating serine proteases are a predominant source of self-antigen for potent T lymphocyte immunity to human leukemia. The Journal of Immunology 178, 2007. e-Pub 2007.
Wang C, Ma Q, Wieder E, Lu S, Molldrem JJ. Ex vivo expansion of PR1-CTL elicited by autologous dendritic cells pulsed with PR1 peptide for adoptive immunotherapy of leukemia. The Journal of Immunology 178, 2007. e-Pub 2007.
Ishiyama K, Kondo Y, Wieder E, Lu S, Molldrem J. Aberrantly expressed neutrophil elastase (ELA2) in the nucleus and cytoplasm of acute lymphocytic leukemia (ALL) cells cleaves cyclin E (CCNE) into low-molecular-weight forms (LMWFs) yielding novel HLA-A2 restricted determinants. The Journal of Immunology 178, 2007. e-Pub 2007.
Rusakiewicz S, Kant S, Lizee G, Rabinovich B, Wieder E, Lu S, Hwu P, Molldrem J. CD8 T cells with high avidity TCR-ab specific for serine protease self-determinants for use in adoptive immunotherapy of human leukemia. The Journal of Immunology 178, 2007. e-Pub 2007.
Ishiyama K, Kondo Y, Wieder E, Lu S, Molldrem J. CTL with specificity for cyclin E self-antigen peptides contribute to remission after stem cell transplantation without associated graft-versus-host disease. Biology of Blood and Marrow Transplantation, 2007. e-Pub 2007.
Komanduri KV, St John LS, Bryan S, Martin S, McMannis JD, Molldrem JJ, Champlin RE, Cooper LJ, Worth L, Petropoulos D, Hosing C, Couriel DM, de Lima M, Shpall EJ. Delayed immune recovery after umbilical cord blood transplantation (UCBT) is characterized by thymic regeneration failure. Biology of Blood and Marrow Transplantation 13(11):1400, 2007. e-Pub 2007.
Kim TK, St John LS, Wieder ED, Molldrem JJ, Komanduri KV. Higher-order cytokine flow cytometry reveals distinct funtional signatures of maturation subsets of CD4+ and CD8+ T cells (Poster). Biology of Blood and Marrow Transplantation 13(2):Supplement 1, pages 126-127, 2007. e-Pub 2007.
Ishiyama K, Kondo Y, Wieder E, Lu S, Molldrem J. High avidity cyclin E-derived peptide-specific CTL contribute to induction of remission after stem cell transplantation (Oral Presentation). Biology of Blood and Marrow Transplantation 13(2):Supplement 1, page 32, 2007. e-Pub 2007.
Wang Y, Li D, Jones D, Bassett R, Sale GE, Khalili J, Komanduri KV, Couriel DP, Champlin RE, Molldrem JJ, Ma Q. Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation (Poster). Biology of Blood and Marrow Transplantation 13(2):Supplement 1, pages 112-113, 2007. e-Pub 2007.
Ma Q, Wieder ED, Jones DJ, Wang C, Li DJ, Molldrem JJ. A mouse model of PR1-CTL adoptive cell therapy demonstrates rapid reduction of leukemia burden in both bone marrow and extramedullary organs (Poster). Blood 108(11):1052a, 2006. e-Pub 2006.
Lee ST, Liu S, Sukhumalchandra P, Molldrem J, Hwu P, Liu YJ, Kwak LW, Lizee G, Neelapu SS. A novel strategy for generation of human tumor-specific T cell clones for adoptive transfer (Poster). Blood 108(11):1060a, 2006. e-Pub 2006.
Komanduri KV, Thomas M, St John LS, Xing D, Decker W, Robinson S, Yang H, Molldrem JJ, Champlin RE, McMannis JD, Shpall EJ. Characterization of optimal T cell/dendritic cell (DC) co-culture conditions for ex vivo expansion of antigen-specific human T cells (Poster). Blood 108(11):1044a, 2006. e-Pub 2006.
Komanduri KV, St John LS, Bryan S, Martin S, McMannis JD, Molldrem JJ, Champlin RE, Cooper LJ, Worth L, Petropoulos D, Couriel DR, de Lima M, Shpall EJ. Delayed immune recovery after umbilical cord blood transplantation (UCBT) is characterized by thymic regeneration failure (Oral Session). Blood 108(11):97a, 2006. e-Pub 2006.
Ishiyama K, Kondo Y, Wieder ED, Lu S, Molldrem JJ. Abberrantly expressed neutrophil elastase (ELA2) cleaves cyclin E (CCNE) in the nucleus and cytoplasm of acute lymphocytic leukemia yielding novel leukemia-associated antigens. Blood 108(11), 2006. e-Pub 2006.
Sergeeva A, Ono Y, Molldrem JJ. Elevated serum neutrophil elastase but not proteinase 3 is present in patients with myeloid leukemia. Blood 108(11), 2006. e-Pub 2006.
Bollard CM, Myers GD, Leen A, Huls H, Buza E, Chang J, Leung K, Carrum G, Krance RA, Molldrem J, Brenner MK, Rooney CM, Heslop HE. The clinical use of donor-derived virus-specific cytotoxic T lymphocytes reactive against cytomegalovirus (CMV) adenovirus, and epstein barr virus (EBV) (Poster). Biology of Blood and Marrow Transplantation 12(2):77, 2006. e-Pub 2006.
Qazilbash MH, Rios R, Thall PF, Wang X, Wieder E, Lu S, Kant S, Giralt SA, Estey EH, Cortes J, Champlin RE, Komanduri KV, Molldrem JJ. PR1 vaccine after hematopoietic stem cell transplantation (Oral Presentation). Biology of Blood and Marrow Transplantation 12(2):Supplement 1, page 16, 2006. e-Pub 2006.
Ishiyama K, Kondo Y, Wieder E, Lu S, Orozco N, Dong C, Neelapu S, Hwu P, Liu Y, Kwak L, Molldrem J. High avidity PD-1 cyclin E-specific CTL contribute to leukemia remission and may be induced by epitope spread. The Journal of Immunology A77:141.5, 2006. e-Pub 2006.
Komanduri K, Ozdemir E, Martins S, Lekakis K, Wieder E, Molldrem J, Shpall E, de Lima M, McMannis J, St John L. Functional T cell immunity in allogeneic stem cell transplantation (Poster). Measuring Antigen-Specific Immune Responses, 2006 MASIR Annual Meeting, 2006. e-Pub 2006.
Kondo Y, Feng X, Lu X, Mochizuki K, Molldrem JJ, Nakao S. Two cyclin-dependent kinase derived peptides are potential leukemia-associated-antigens able to eradicate acute myeloid leukemia cells after allogeneic stem cell transplantation (Poster). Blood 106(11):868a, 2005. e-Pub 2005.
Ishiyama K, Wieder E, Lu S, Molldrem J. High avidity cyclin E-derived peptide-specific CTL contribute to induction of remission after stem cell transplantation without associated graft-versus-host disease (Poster). Blood 106(11):411a, 2005. e-Pub 2005.
Sergeeva A, Wieder E, Milam N, Ono Y, Rios R, Molldrem JJ. Pre-existing anti-GM-CSF autoantibodies in patients with AML, CML and MDS are associated with compromised immune response to PR1 peptide vaccination (Poster). Blood 106(11):910a, 2005. e-Pub 2005.
Ono Y, Lu S, Sergeeva A, Wang C, Wieder E, Molldrem JJ. PR1 leukemia-associated antigen is cross-presented by B cells from soluble serum proteases (Poster). Blood 106(11):674a, 2005. e-Pub 2005.
Kondo Y, Wieder E, Lu S, Molldrem JJ. High avidity cyclin E1-derived peptide-specific CTL kill lymphoid leukemia cells and cross-recognize a homologous cyclin E2-derived peptide (Poster). Biology of Blood and Marrow Transplantation 11(2):Supplement 1, page 61, 2005. e-Pub 2005.
Komanduri KV, St John LS, Shpall EJ, Champlin RE, Molldrem JJ, Ozdemir E. CMV reactivation after allogeneic stem cell transplantation is associated with a preponderance of circulating late-stage CMV-specific CD8+ T cells. Blood 106:908a, 2005. e-Pub 2005.
Kondo Y, Wieder E, Lu S, Molldrem JJ. High avidity cyclin E1-derived peptide-specific CTL kill lymphoid leukemia cells and cross-recognized a homologous cyclin E2-derived peptide. Blood 104(11):207b, 2004. e-Pub 2004.
Sergeeva A, Ono Y, Rios R, Molldrem JJ. IgG, IgA and IgM autoantibodies to GM-CSF are present in AML, CML and MDS patients and IgG titer is associated with disease progression (Poster). Blood 104(11):304a, 2004. e-Pub 2004.
Ogasawara Y, Nakayama K, Tarnowka M, McCoy JP, Molldrem JJ, Levin BC, Kajigaya S, Young NS. Mitochondrial DNA (mtDNA) sequence heterogeneity among and within single human CD34 cells, T cells, B cells and granulocytes. Blood 104(11):879a, 2004. e-Pub 2004.
Qazilbash MH, Wieder E, Rios R, Lu S, Kant S, Giralt S, Estey EH, Thall P, de Lima M, Couriel D, Champlin RE, Komanduri K, Molldrem JJ. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia (Oral Session). Blood 104(11):77a, 2004. e-Pub 2004.
Ono Y, Kondo Y, Sergeeva A, Akande O, Sukhumalchandra P, Lu S, Wieder E, Molldrem JJ. Antigen cross-presentation allows the PR1 leukemia-associated antigen to be processed from both proteinase 3 and neutrophil elastase to prime T cells (Poster). Blood 104(11):886a, 2004. e-Pub 2004.
Molldrem J, Komanduri K, Qazilbash M. Is there significant immune therapy in CML?, 2004. e-Pub 2004.
Molldrem JJ. Primary granule proteins as targets of immunotherapy for myeloid forms of leukemia. International Society for Cellular Therapy's (ISCT) 10th Annual Meeting, 2004. e-Pub 2004.
Ono Y, Kondo Y, Lu S, Molldrem JJ. The PR1 leukemia-associated antigen is endogeneously processed and presented from both proteinase 3 and neutrophil elastase and is recognized by T lymphocytes (Poster). Blood 102(11):694a, 2003. e-Pub 2003.
Kondo Y, Lu S, Ding X, He D, Wieder E, Molldrem JJ. Cyclin E2 peptide-specific CTL clone shows cross recognition of a homologous cyclin E1 peptide and kills lymphoid and myeloid leukemia cells (Poster). Blood 102(11):701a, 2003. e-Pub 2003.
Wieder ED, Kant S, Lu S, He Z, Molldrem JJ. PR1 peptide vaccination of myeloid leukemia patients induces PR1-specific CTL with high CCR7 expression (Poster). Blood 102(11):611a, 2003. e-Pub 2003.
Molldrem JJ, Kobayashi S, Morris K. Predicting response of patients with MDS to antithymocyte globulin (ATG) by T cell clonal dominance. 65th Annual Meeting of the Japanese Society of Hematology and the 45th Annual Meeting of the Japanese Society of Clinical Hematology, 2003. e-Pub 2003.
Kondo Y, Lu S, Wang C, Molldrem JJ. Two HLA-A2-restricted peptides from cyclin E1 and cyclin E2 elicit CTL that kill myeloid leukemia cell line. Biology of Blood and Marrow Transplantation 9(2):61, 2003. e-Pub 2003.
Wang C, Lu S, Kinds ZR, Sukhumalchandra P, Molldrem JJ. Dendritic cells cultured with interferon plus GM-CSF can be used to elicit PR1-specific CTL for adoptive immunotherapy (Poster). Biology of Blood and Marrow Transplantation 9(2):95, 2003. e-Pub 2003.
Ono Y, St John L, Lu S, Wang C, Molldrem J. The leukemia-associated antigen PR1 is derived from both proteinase 3 and neutrophil elastase proteins (Poster). Biology of Blood and Marrow Transplantation 9(2):92-93, 2003. e-Pub 2003.
Couriel DR, Hicks K, Giralt S, Ippoliti C, Khouri I, de Lima M, Horton E, Cohen A, Hosing C, Donato M, Anderlini P, Molldrem JJ, Gajewski J, Champlin R. Phase III trial with infliximab/methylprednisolone (MP) vs MP for the treatment of acute GVHD: preliminary findings (Poster). Biology of Blood and Marrow Transplantation 9(2):Page 95, 2003. e-Pub 2003.
Kobayashi S, Kochenderfer J, Morris K, He D, Wieder E, Molldrem JJ. Autologous bone marrow-derived antigens drive clonal expansions of T cells that secrete interferon-gamma and TNF-Alpha in patients with myelodysplastic syndrome and cytopenia (Poster). Blood 100(11), 2002. e-Pub 2002.
Molldrem JJ, Kant S, Lu S, Rios R, Streicher H, Wang C, Giralt S, O Brien S, Cortes J, Champlin R, Martin T, Wieder E. Peptide vaccination with PR1 elicits active T cell immunity that induces cytogenetic remission in acute myelogenous leukemia (Plenary session). Blood 100(11):6a, 2002. e-Pub 2002.
Amrolia PJ, Yvon E, Huls H, Bollard C, Wieder E, Molldrem JJ, Rooney C, Heslop H, Kuehnle I, Malcolm BK. Selective depletion of donor alloreactive T cells without loss of anti-viral or anti-leukemic responses using an anti-CD25 immunotoxin (Simultaneous Session). Blood 100(11), 2002. e-Pub 2002.
Komanduri KV, Dorsam S, St John LS, Wieder ED, Champlin RE, Molldrem JJ, McCormick F, Haqq C. Genomic expression analysis of activated cytomegalovirus-specific human CD4+ T cells (Poster). Blood 100(11), 2002. e-Pub 2002.
Sinha M, Molldrem JJ. A single nucleotide polymorphism in proteinase 3 that codes for HLA-A2-Binding peptides protects against development of acute myelogenous leukemia. Blood 94(11), 2002. e-Pub 2002.
Komanduri KV, Ozdemir E, Gillespie GM, St John LS, Rowland-Jones S, Champlin RE, Molldrem JJ. Definitive evidence for an immunodominance heirarchy in the human CD8+ T cell response to cytomegalovirus. Blood 100(11), 2002. e-Pub 2002.
Battiwalla M, Saunthararajah S, Nakamura R, Wisch L, Melenhorst J, Molldrem J, Barrett AJ. Treatment of T-LGL (Large Granular Lymphocytic Disease) with cyclosporine A - long term follow-up. Blood 100(11), 2002. e-Pub 2002.
Kant S, Wider E, Lu S, Kantarjian H, Talpaz M, Molldrem JJ. High affinity PR1-specific T cells participate in the maintenance of cytogenetic remission in interferon-sensitive chronic myelogenous leukemia patients off all therapy. Blood 100(11), 2002. e-Pub 2002.
Ozdemir E, St John LS, Gillespie G, Rowland-Jones S, Champlin RE, Molldrem JJ, Komanduri KV. Cytomegalovirus-specific CD8+ T cell recovery, as measured by HLA-peptide tetramer straining, is insufficient to control viremia following allogeneic stem cell transplantation (Poster). Blood 98(11):389a, 2001. e-Pub 2001.
Kant S, Wieder ED, Lu S, Molldrem JJ. Induction of a high affinity allogeneic PR1-specific CTL response is associated with cytogenetic remission after PR1 peptide vaccine (Poster). Blood 98(11):652a, 2001. e-Pub 2001.
Lu S, Wieder ED, He Z, Fernandez C, Giralt S, Champlin RE, Molldrem JJ. Immunity to a novel myeloperoxidase peptide, proteinase 3 and the HA-1 minor antigen is present in AML patients that respond to nonablative stem cell transplant. Blood 98(11):855a, 2001. e-Pub 2001.
Jiang W, Tari AM, Lee PP, Lopez-Berenstein G, Davis MM, Molldrem JJ. Peptide/MHC monomers can be inserted into artificial lipid bilayers as artificial antigen presentation constructs. Blood 98(11):509a, 2001. e-Pub 2001.
Wieder ED, Kant S, Lu S, He Z, Wang C, Huddleston H, O Brien S, Giralt S, Champlin RE, Molldrem JJ. Effective specific immunity induced after PR1 peptide vaccination correlates with cytogenetic remission (Poster). Blood 98(11):407a, 2001. e-Pub 2001.
Braunschweig I, Wang C, Molldrem J. Cytotoxic T lymphocytes (CTL) specific for myeloperoxidase-derived HLA-A2-restricted peptides specifically lyse AML and CML cells (Poster). Blood 96(11):761a, 2000. e-Pub 2000.
Kochenderfer J, Felio K, Kinds Z, Molldrem J. Molecular analysis of the T cell repertoire reveals dominant clonal T cells that persist in ATG-refractory MDS patients. Blood 96(11):834a, 2000. e-Pub 2000.
Su C, Wang C, Molldrem J. Expression of the leukemia-associated antigen proteinase 3 and neutrophil elastase is transcriptionally upregulated by interferon-a2b and GM-CSF in CD34+ CML cells (Poster). Blood 96(11):170a, 2000. e-Pub 2000.
Darnay BG, Wang C, Aggarwal BB, Hernandez C, Melenhorst JJ, Barrett AJ, Rath P, Singh S, Molldrem JJ. Survival of T-LGL leukemia cells is associated with expression and constitutive activation of the anti-apoptosis receptor RANK and RANK ligand on T-LGL cells (Poster). Blood 94(11):187, 1999. e-Pub 1999.
Dang NH, Melenhorst J, Barrett AJ, Molldrem JJ. CD26 as a marker for clinically aggressive T-LGL leukemia. Blood 94(11):4094, 1999. e-Pub 1999.
Braunschweig I, Wang C, Molldrem JJ. Cytotoxic T lymphocytes (CTL) recognize a HLA-A2.1-restricted peptide derived from myeloperoxidase, a leukemia-associated protein. Blood 94(11):1445, 1999. e-Pub 1999.
Melenhorst J, Bummendorf T, Kim S, Dirby M, Sloand E, Bahceci E, Sorbara L, Molldrem JJ, Lansdorp P, Barrett AJ. Large granular T cell lymphocytosis (LGL) is an unresolved CD8+ immune response. Blood 94(11):2799, 1999. e-Pub 1999.
Giralt S, Khouri I, Braunschweig I, Ippolitti C, Donato M, Cohen A, Davis M, Andersson B, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno N, Molldrem J, Champlin R. Melphalan and purine analog containing preparative regimens: Less intensive conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation (PCT). Blood 94(11):2518, 1999. e-Pub 1999.
Gajewski JL, Donato M, Anderlini P, Korbling M, Saliba R, Khouri I, Rondon G, Giralt S, Ueno N, Andersson B, Molldrem J, Ippoliti C, Buzdar A, Valero V, Bast R, Theriault R, Hortabagyi G, Champlin R. Intensive chemotherapy with G-CSF mobilization yields improved peripheral blood progenitor cell (PBPC) collection, quicker recovery after high dose chemotherapy (HDC) and reduces progression risk compared to G-CSF alone for mobilization (Simultaneous Oral Session). Blood 94(11):2953, 1999. e-Pub 1999.
Molldrem JJ, Rivera M, Stetler-Stevenson M, Saborro L, Barrett AJ. Treatment with low-dose cyclosporine induces sustained recovery from cytopenia in patients with T-LGL leukemia (Poster). Blood 94(11):1326, 1999. e-Pub 1999.
Shimoni A, Anderlini P, Andersson B, Andreeff M, Braunschweig I, Claxton D, Cohen A, Donato M, Estey E, Gajewski J, Khour I, Korbling M, Kornblau S, Molldrem J, Ueno N, Champlin R, Giralt S. Allogeneic transplantation for leukemia in patients older than 60 years: age should not exclude treatment with non-myeloablative regimens. Blood 94(11):3138, 1999. e-Pub 1999.
Saunthararajah Y, Molldrem J, Rivera M, Young N, Barrett AJ. Coincidence of T-LGL with myelodysplastic syndrome is associated with a poor response of cytopenia to therapy with cyclosporine. Blood 94(11):429, 1999. e-Pub 1999.
Molldrem JJ, Lee PP, Wang C, Champlin RE, Kantarjian HM, Davis MM, Hernandez C, Felio K. Cytotoxic T lymphocytes (CTL) specific for the PR1 leukemia antigen are increased in the majority of CML patients with complete cytogenetic responses to interferon and in allogeneic bone marrow transplant recipients (Poster). Blood 94(11):1446, 1999. e-Pub 1999.
Shimoni A, Anderlini P, Andersson B, Braunschweig I, Claxton D, Donato M, Gajewski J, Kantarjian H, Khouri I, Korbling M, Kornblau S, Molldrem J, Talpaz M, Ueno N, Champlin R, Giralt S. CD8-depleted donor lymphocyte infusion (DLI) for the treatment of CML relapse after allogeneic transplant: Long-term follow-up and factors predicting outcome. Blood 94(11):700, 1999. e-Pub 1999.
Gajewski J, Donato M, Anderlinie P, Korbling M, Khouri I, Rondon G, Giralt S, Buzdar A, Ueno N, Andersson B, Durrett A, Saliba R, Bruton J, Molldrem J, Ippoliti C, Raber M, Bast R, Hortabagyi G, Champlin R. Preliminary results of a randomized trial comparing intensive chemotherapy with growth factor (GF) for peripheral blood progenitor cell (PBPC) mobilization to growth factor alone for hematopoietic rescue after high dose chemotherapy (HDC). American Society of Clinical Oncology Annual Meeting, 1999. e-Pub 1999.
Molldrem JJ, Lee PP, Davis MM. High dose antigen induces apoptosis of high avidity cytotoxic T lymphocytes (CTL) specific for a myeloid self-peptide. Keystone Symposia on Molecular and Cellular Biology, 1999. e-Pub 1999.
Jabbour NK, Fukushima PI, Jasper GA, Rick M, Molldrem J, Barrett J, Stetler-Stevenson M. Flow cytometric detection of dyspoiesis in myelodysplastic syndrome. 13th Annual Clinical Applications in Cytometry, 1998. e-Pub 1998.
Stetler-Stevenson M, Jabbour NK, Jukushima PI, Jasper GA, Rick M, Molldrem J, Barrett J. Flow cytometry is more sensitive than morphology in detecting dyspoiesis in myelodysplastic syndrome. American Society of Clinical Oncology Annual Meeting, 1998. e-Pub 1998.
Raptis A, Mavroudis D, Molldrem J, Childs R, Ledakis P, Bahceci E, F va R, Hensel N, Phang S, Barrett AJ. High dose methylprednisolone improves outcome of diffuse alveolar hemorrhage (DAH) following bone marrow transplantation (BMT) for hematological malignancies. American Society of Clinical Oncology Annual Meeting, 1998. e-Pub 1998.
Elenitoba-Johnson KSJ, Medeiros LJ, Taubenberger JK, Molldrem J, Fukushia P, Stetler-Stevenson M. T-cell large granular lymphocytosis (TLGL): Comparison of clinical criteria and results of immunophenotypic and molecular studies. Laboratory Investigation 76:124A, 1997. e-Pub 1997.
Molldrem J, Dermime S, Parker K, Mavroudis D, Jiang YZ, Hensel N, Barrett AJ. Cytotoxic T lymphocytes specific for a MHC class I-restricted peptide derived from the leukemia-associated protein proteinase 3 also show specificity toward fresh leukemic cells. American Society of Clinical Oncology Annual Meeting, 1996. e-Pub 1996.
Mavroudis DA, Molldrem J, Barrett AJ. Bone marrow CD34+ cell dose correlates with transplant related mortality and survival in HLA identical sibling BMT for hematologic malignancies. American Society of Clinical Oncology Annual Meeting, 1996. e-Pub 1996.

Book Chapters

Alatrash G, Molldrem JJ. Vaccine Therapy. In: Williams Hematology. McGraw Hill, 2020.
Al Atrash G, Molldrem JJ. T Cell Receptor Mimic Antibodies. In: Immunotherapy in Translational Research. Wiley, 2018.
Alatrash G, Crain AK, Molldrem JJ. Tumor Associated Antigens. In: Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation". Elsevier, 2018.
Alatrash G, Molldrem JJ. Tumor-associated antigens. In: Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation. Elsevier, Inc, 143-59, 2013.
Alatrash G, Molldrem JJ. Immunotherapy of AML. In: Acute Myelogenous Leukemia: Genetics, Biology and Therapy. Springer, 237-256, 2010.
Riddell S, Molldrem JJ. Understanding and enhancing the graft-versus-leukemia effect after hematopoietic stem cell transplantation. In: Hematopoietic Stem Cell Transplantation. Springer, 2008.
Kurbegov D Molldrem J. Peptide Vaccination of Myeloid Leukemia. In: Regenerative and Cell Therapy, Clinical Advances. Ernst Schering Research Foundation Workshop, 131-144, 2005.
Molldrem JJ Shlomchik W. Graft-vs-Leukemia Effects. In: Graft vs. Host Disease. Marcel Dekker, Inc, 155-193, 2003.
Molldrem JJ. Tissue Antigens as Targets for GVL. In: Allogeneic Immunotherapy. Marcel Dekker, Inc, 135-155, 2000.
Molldrem JJ. T Cell Large Granular Lymphocyte Lymphoproliferative Disorder. In: Bone Marrow Failure Syndromes. Saunders, 207-215, 2000.
Roth J, Molldrem J, Smythe W. The Current Status of Cancer Gene Therapy Trials. In: Cancer: Principles and Practice of Oncology Updates. Lippincott-Raven, 1-15, 1999.

Patents

Monoclonal Antibodies for Use in Diagnosis and Therapy of Cancers and Autoimmune Disease. Patent Number: MDA09-014; PCT/9,926,380 B2.

Less

CV information above last modified March 06, 2026

Jeffrey Joel Molldrem, M.D.

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Patents

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Jeffrey Joel Molldrem, M.D.

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Patents

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson